Companies

0

Speakers

0

Seats

0

Investors

0

Partners

0

Precision Medicine Community United

AAPM is on the mission to unite the precision medicine community. The 2021 Annual Meeting is bringing together, scientists, clinicians, patient advocates, entrepreneurs, investors, industry executives as well as other precision medicine experts, to share their insights. AAPM2021 is also designed to facilitate a dialogue between the 4-P’ of precision medicine: Patients, providers, public health planers (Government) and payers to work together to achieve the goal of delivering improved outcomes at reduced costs. The conference is also designed to set the research and development goals for the international precision medicine community.

REGISTER NOW
Precision Medicine Community United

AAPM Believes that

• Precision medicine field will transform our healthcare sector in the next decade and will play a crucial role in US as well as the global economy.
• Promoting a cross talk between technology & healthcare sectors will accelerate innovation.
• Showcasing successful companies/institutions, leaders/executives, with a well-deserved recognition, will boost stake holder confidence to perform better.
• Sharing best practices, case studies, and research findings will benefit the community.
• By helping precision medicine field grow and prosper, AAPM will market United States as an investment hub for the rest of the world.

REGISTER NOW
AAPM Believes that

Who’s Speaking?

AAPM 2021 Speakers

Lynsey ChediakLead, Global Health at World Economic Forum

Lynsey is the former Founder and CEO of a patient advocacy non-profit where she implemented new models for increased patient engagement and support across hospital systems in the US. She wrote public health policy in the California Governor’s Office including a campaign to get calorie counts on restaurant menus state-wide and health policy in the UK’s Parliament, House of Commons, expanding minimum length of care for paediatric rare disease patients in the National Health Service (NHS). She also co-led a digital media start-up providing branding and marketing services as one of 100 entrepreneurs in the USA selected to complete the Venture for America Fellowship. Lynsey holds a BA from Claremont McKenna College and MSc from the London School of Economics and Political Science. Lynsey is a rare disease patient, an active patient advocate, and a spokesperson for Shriners Hospitals for Children, Northern California.

Lynsey ChediakLead, Global Health at World Economic Forum

Lynsey is the former Founder and CEO of a patient advocacy non-profit where she implemented new models for increased patient engagement and support across hospital systems in the US. She wrote public health policy in the California Governor’s Office including a campaign to get calorie counts on restaurant menus state-wide and health policy in the UK’s Parliament, House of Commons, expanding minimum length of care for paediatric rare disease patients in the National Health Service (NHS). She also co-led a digital media start-up providing branding and marketing services as one of 100 entrepreneurs in the USA selected to complete the Venture for America Fellowship. Lynsey holds a BA from Claremont McKenna College and MSc from the London School of Economics and Political Science. Lynsey is a rare disease patient, an active patient advocate, and a spokesperson for Shriners Hospitals for Children, Northern California.

closepopup
Prasun J. Mishra, PhDFounder, CEO, American Association for Precision Medicine (AAPM)

Dr. Mishra (formerly with Genentech, Roche, NCI, NIH, DHHS, US Government) is a seasoned innovation executive leading research efforts focused on preventing and curing COVID-19, cancer, and other chronic diseases. Dr. Mishra also served as a Principal Investigator at Genentech, Roche. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics, and several drugs/ combinations in the clinic.

Widely recognized as a technology and healthcare thought leader, Dr. Mishra has keynoted, chaired, curated, and organized numerous successful international conferences. His research work has been recognized globally by over 40 prestigious awards and honors. Due to his unique perspective & selfless service, he is highly respected & sought-after mentor to many.

Prasun J. Mishra, PhDFounder, CEO, American Association for Precision Medicine (AAPM)

Dr. Mishra (formerly with Genentech, Roche, NCI, NIH, DHHS, US Government) is a seasoned innovation executive leading research efforts focused on preventing and curing COVID-19, cancer, and other chronic diseases. Dr. Mishra also served as a Principal Investigator at Genentech, Roche. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics, and several drugs/ combinations in the clinic.

Widely recognized as a technology and healthcare thought leader, Dr. Mishra has keynoted, chaired, curated, and organized numerous successful international conferences. His research work has been recognized globally by over 40 prestigious awards and honors. Due to his unique perspective & selfless service, he is highly respected & sought-after mentor to many.

closepopup
Shannon Muir, PhDCo-Director California Initiative to Advance Precision Medicine, California Governor's Office

Dr. Muir co-leads the California Initiative to Advance Precision Medicine. In this role, she works with the Precision Medicine Advisory Council and the Governor’s Office in the selection and management of grants for precision medicine demonstration projects. Her current portfolio consists of projects that aim to address health disparities in cancer prevention and treatment. Dr. Muir also manages strategic relationships with State entities and other stakeholders including community groups, academics, and private sector partners. She previously served as a Director of the Research Proposal Development Service at UC San Diego, as well as a Senior Program Associate and Science and Technology Policy Fellow in the Senate Health Committee for the California Council on Science and Technology. Dr. Muir received a PhD in Biomedical Sciences from UC San Diego, an MS in Pharmacology from Tulane University, and BS in Psychobiology from UCLA.

Shannon Muir, PhDCo-Director California Initiative to Advance Precision Medicine, California Governor's Office

Dr. Muir co-leads the California Initiative to Advance Precision Medicine. In this role, she works with the Precision Medicine Advisory Council and the Governor’s Office in the selection and management of grants for precision medicine demonstration projects. Her current portfolio consists of projects that aim to address health disparities in cancer prevention and treatment. Dr. Muir also manages strategic relationships with State entities and other stakeholders including community groups, academics, and private sector partners. She previously served as a Director of the Research Proposal Development Service at UC San Diego, as well as a Senior Program Associate and Science and Technology Policy Fellow in the Senate Health Committee for the California Council on Science and Technology. Dr. Muir received a PhD in Biomedical Sciences from UC San Diego, an MS in Pharmacology from Tulane University, and BS in Psychobiology from UCLA.

closepopup
Ritesh JainCo-Founder, Infynit, Former COO HSBC, Advisor G20 GPFI, Harvard Business Review and MIT

Ritesh is a Co-Founder at Infynit - Humanising Credit and Credit Cards, he is a Former COO at HSBC. He is an Entrepreneurial Technology Leader & Board Advisor with global experience across various sectors including Payments & Banking, He led the future of payments for VISA and introduced Apple Pay, built a wealth management company as a founder CTO. Presently, he is a member of a G20 Initiative for financial inclusion; Advisor to Open Banking in EU & Africa, Harvard Business Review (HBR), payment regulators and government bodies for the initiative in social and financial inclusion and a member of MIT Global Tech Panel. Past roles include mentor to the UK Parliament Digital Service & Startups.

Ritesh JainCo-Founder, Infynit, Former COO HSBC, Advisor G20 GPFI, Harvard Business Review and MIT

Ritesh is a Co-Founder at Infynit - Humanising Credit and Credit Cards, he is a Former COO at HSBC. He is an Entrepreneurial Technology Leader & Board Advisor with global experience across various sectors including Payments & Banking, He led the future of payments for VISA and introduced Apple Pay, built a wealth management company as a founder CTO. Presently, he is a member of a G20 Initiative for financial inclusion; Advisor to Open Banking in EU & Africa, Harvard Business Review (HBR), payment regulators and government bodies for the initiative in social and financial inclusion and a member of MIT Global Tech Panel. Past roles include mentor to the UK Parliament Digital Service & Startups.

closepopup
Erika Hanson BrownCEO/Co-Founder PALTOWN Development Foundation, Patient Advocate

Brown, a Montana native, had a healthy career as a corporate executive search professional until - at age 58 – she was diagnosed with late-stage colorectal cancer. Treatment completed, her interests refocused upon the undeveloped niche of disease-specific patient empowerment.
Recently founding the PALTOWN DEVELOPMENT FOUNDATION.
PALTOWN supports its first "TUMOR TOWN": COLONTOWN, an online, deeply engaged community dedicated to CRC patients and family members.
COLONTOWN provides a successful template and model for community-building for other disease states.
Brown is grateful, empowered, and disease-free - 18 years later.

Erika Hanson BrownCEO/Co-Founder PALTOWN Development Foundation, Patient Advocate

Brown, a Montana native, had a healthy career as a corporate executive search professional until - at age 58 – she was diagnosed with late-stage colorectal cancer. Treatment completed, her interests refocused upon the undeveloped niche of disease-specific patient empowerment.
Recently founding the PALTOWN DEVELOPMENT FOUNDATION.
PALTOWN supports its first "TUMOR TOWN": COLONTOWN, an online, deeply engaged community dedicated to CRC patients and family members.
COLONTOWN provides a successful template and model for community-building for other disease states.
Brown is grateful, empowered, and disease-free - 18 years later.

closepopup
Luigi Fontana, MD, Ph.D., FRACPDirector, Healthy Longevity Program at Charles Perkins Centre, University of Sydney

Professor Luigi Fontana, MD, PhD, FRACP, is Professor of Medicine and Nutrition in the Faculty of Medicine and Health at the University of Sidney, Leonard P. Ullman Chair in Translational Metabolic Health, Director of the Healthy Longevity Research and Clinical Program, and a Clinical Academic in the Department of Endocrinology at the Royal Prince Alfred Hospital in Sydney, Australia. Luigi is an internationally recognized physician scientist who studies healthy longevity, with a focus on calorie restriction, endurance exercise and metabolism. He is currently the Leonard P Ullmann Chair in Translational Metabolic Health at the Charles Perkins Centre, where he directs the Healthy Longevity Research and Clinical Program. Fontana received his medical training at the University of Verona in Italy and graduated with honors in 1994. After two years as intern and resident at the University of Verona Medical School, Fontana joined the Laboratory of Clinical Pharmacology at the King's College School of Medicine, University of London in 1997. He returned to University of Verona in 1998 to become Chief Medical Resident in Internal and Emergency Medicine and graduated in 1999. In 2004 he completed his PhD in Metabolism at University of Padova School of Medicine in Italy. He is the recipient of three prestigious awards: the 2009 American Federation for Aging Research (AFAR) Breakthroughs in Gerontology Award, the 2011 Glenn Award for Research in Biological Mechanisms of Aging, and the 2016 Vincent Cristofalo Award of the American Federation for Aging Research. He was a Scientific Member of the Board of Directors of the American Aging Association, and is the Editor in Chief of the scientific journal "Nutrition and Healthy Aging". Luigi is interested in preventive medicine and in the mechanisms mediating healthy longevity in humans, focusing on nutrition, physical exercise and caloric restriction mimetics.

Luigi Fontana, MD, Ph.D., FRACPDirector, Healthy Longevity Program at Charles Perkins Centre, University of Sydney

Professor Luigi Fontana, MD, PhD, FRACP, is Professor of Medicine and Nutrition in the Faculty of Medicine and Health at the University of Sidney, Leonard P. Ullman Chair in Translational Metabolic Health, Director of the Healthy Longevity Research and Clinical Program, and a Clinical Academic in the Department of Endocrinology at the Royal Prince Alfred Hospital in Sydney, Australia. Luigi is an internationally recognized physician scientist who studies healthy longevity, with a focus on calorie restriction, endurance exercise and metabolism. He is currently the Leonard P Ullmann Chair in Translational Metabolic Health at the Charles Perkins Centre, where he directs the Healthy Longevity Research and Clinical Program. Fontana received his medical training at the University of Verona in Italy and graduated with honors in 1994. After two years as intern and resident at the University of Verona Medical School, Fontana joined the Laboratory of Clinical Pharmacology at the King's College School of Medicine, University of London in 1997. He returned to University of Verona in 1998 to become Chief Medical Resident in Internal and Emergency Medicine and graduated in 1999. In 2004 he completed his PhD in Metabolism at University of Padova School of Medicine in Italy. He is the recipient of three prestigious awards: the 2009 American Federation for Aging Research (AFAR) Breakthroughs in Gerontology Award, the 2011 Glenn Award for Research in Biological Mechanisms of Aging, and the 2016 Vincent Cristofalo Award of the American Federation for Aging Research. He was a Scientific Member of the Board of Directors of the American Aging Association, and is the Editor in Chief of the scientific journal "Nutrition and Healthy Aging". Luigi is interested in preventive medicine and in the mechanisms mediating healthy longevity in humans, focusing on nutrition, physical exercise and caloric restriction mimetics.

closepopup
John Mattison, MD.Chief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente

John Mattison, MD is the Chief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente. He focuses on transforming care delivery with information technology, through convergence of exponential technologies and data liquidity. He led the design and implementation of the largest integrated electronic health record in the US, and leads various national programs including virtual care. He has sponsored or led numerous digital innovations, and mentors many digital health startups. He chairs the eHealth Workgroup of the Global Alliance for Genomics and Health (GA4GH), and is a board member of Open mHealth, advisory board member of the NIH funded Policy and Ethics in Precision Medicine, teaches at multiple Universities including Singularity University, and has published widely on privacy, policy, security, IOT, global genomics collaboration, interoperability, mobile health, and healthcare transformation. He has published in Nature, JAMIA, JAMA, WSJ, Forbes, and has authored chapters for various books. He has keynoted or hosted many national and international healthcare conferences and has consulted in many countries. He is the founder of the international XML standard for health record interoperability known as CDA, CCD and CCDA, and is an active participant on several global initiatives to bring internet services to underserved communities providing access to both jobs and healthcare.

John Mattison, MD.Chief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente

John Mattison, MD is the Chief Medical Information Officer, Assistant Medical Director, Emeritus, Kaiser Permanente. He focuses on transforming care delivery with information technology, through convergence of exponential technologies and data liquidity. He led the design and implementation of the largest integrated electronic health record in the US, and leads various national programs including virtual care. He has sponsored or led numerous digital innovations, and mentors many digital health startups. He chairs the eHealth Workgroup of the Global Alliance for Genomics and Health (GA4GH), and is a board member of Open mHealth, advisory board member of the NIH funded Policy and Ethics in Precision Medicine, teaches at multiple Universities including Singularity University, and has published widely on privacy, policy, security, IOT, global genomics collaboration, interoperability, mobile health, and healthcare transformation. He has published in Nature, JAMIA, JAMA, WSJ, Forbes, and has authored chapters for various books. He has keynoted or hosted many national and international healthcare conferences and has consulted in many countries. He is the founder of the international XML standard for health record interoperability known as CDA, CCD and CCDA, and is an active participant on several global initiatives to bring internet services to underserved communities providing access to both jobs and healthcare.

closepopup
Lynda Chin, MDFounder, CEO, Apricity Health LLC, Adjunct Professor of Oncology, Dell Medical School

Dr. Chin is an elected member of the National Academy of Medicine, a renowned cancer genomic scientist and a leader in application of technologies, AI/ML and big data in medicine. A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute. As the founding chair of Department of Genomic Medicine at MD Anderson, Dr. Chin developed cross-cutting capabilities with technologies, data and analytics, including the APOLLO platform to systematize workflows for patient-oriented research, the Translational Research Accelerator (TRA) to integrate longitudinal clinical and research data to democratize evidence-based care. Later, as Chief Innovation Officer of the University of Texas System, Dr. Chin launched Project DOC to incorporate digital technologies in chronic disease management for the underserved. She conceptualized and demonstrated feasibility of REDI (Real-world Education, early Detection and Intervention), a framework to orchestrate technology-enabled care in a digitally connected ecosystem. Presently, Dr. Chin is president and CEO of Apricity Health, a next-generation precision oncology company she co-founded to harness real-world patient data and world-class clinical expertise at points of care to improve therapy effectiveness, accelerate research and develop next-generation precision medicine.

Lynda Chin, MDFounder, CEO, Apricity Health LLC, Adjunct Professor of Oncology, Dell Medical School

Dr. Chin is an elected member of the National Academy of Medicine, a renowned cancer genomic scientist and a leader in application of technologies, AI/ML and big data in medicine. A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute. As the founding chair of Department of Genomic Medicine at MD Anderson, Dr. Chin developed cross-cutting capabilities with technologies, data and analytics, including the APOLLO platform to systematize workflows for patient-oriented research, the Translational Research Accelerator (TRA) to integrate longitudinal clinical and research data to democratize evidence-based care. Later, as Chief Innovation Officer of the University of Texas System, Dr. Chin launched Project DOC to incorporate digital technologies in chronic disease management for the underserved. She conceptualized and demonstrated feasibility of REDI (Real-world Education, early Detection and Intervention), a framework to orchestrate technology-enabled care in a digitally connected ecosystem. Presently, Dr. Chin is president and CEO of Apricity Health, a next-generation precision oncology company she co-founded to harness real-world patient data and world-class clinical expertise at points of care to improve therapy effectiveness, accelerate research and develop next-generation precision medicine.

closepopup
Piyush SharmaFormer CEO, Zee News, EIR, UCLA Anderson School of Management and Advisor, Stanford Seed

Piyush Sharma – Former CEO Zee News, Executive-in-Residence at UCLA – is a global CEO Coach and a C-Suite + Start-up advisor. Piyush has led public-listed multi-billion-dollar organizations as CEO for India and APAC region. He is an awarded top-rated global business leader, celebrated speaker, top influencer, and sought-after thought leader.

Piyush represents the interests of United Nations affiliates as an Advisory Board Member and as India Advisor for UNSDGs. He has been exposed to collaborating with the govt on Start-up India mission, Digital India mission, Skill India mission, and Smart Cities mission.

Piyush is a member of the board at IIT Delhi for Technology Business Incubation Unit besides being a Star Mentor of Change at Niti Aayog and a Member of the Mentor Board at Ashoka University. He is the India partner for the prestigious ‘World Internet Project’ of the University of Southern California. He is the India Senator of World Business Angel Investment Fund – an affiliate partner of G20 Global Partnership for Financial Inclusion (GPFI).

Piyush’s first book is scheduled to be out before the end of the year. He collaborates with Prof Rajendra Srivastava, Dean @ ISB, on digital disruptions and a book project. Marshall Goldsmith and he deliver ‘Leadership Thinking Nuggets’ series for Fortune. Besides corporate engagements, his most recent masterclass interventions have been with ET Masterclass, ISB workshops, TiE events, Industry Chamber and Ivy League engagements.

Piyush is an international keynote speaker and is sought out by the national and international media alike. His in-depth work as a certified mediation and Yoga teacher and as a master story-teller facilitate transformational leadership and capability building. Follow Piyush’s writings in Forbes and Fortune.

Piyush SharmaFormer CEO, Zee News, EIR, UCLA Anderson School of Management and Advisor, Stanford Seed

Piyush Sharma – Former CEO Zee News, Executive-in-Residence at UCLA – is a global CEO Coach and a C-Suite + Start-up advisor. Piyush has led public-listed multi-billion-dollar organizations as CEO for India and APAC region. He is an awarded top-rated global business leader, celebrated speaker, top influencer, and sought-after thought leader.

Piyush represents the interests of United Nations affiliates as an Advisory Board Member and as India Advisor for UNSDGs. He has been exposed to collaborating with the govt on Start-up India mission, Digital India mission, Skill India mission, and Smart Cities mission.

Piyush is a member of the board at IIT Delhi for Technology Business Incubation Unit besides being a Star Mentor of Change at Niti Aayog and a Member of the Mentor Board at Ashoka University. He is the India partner for the prestigious ‘World Internet Project’ of the University of Southern California. He is the India Senator of World Business Angel Investment Fund – an affiliate partner of G20 Global Partnership for Financial Inclusion (GPFI).

Piyush’s first book is scheduled to be out before the end of the year. He collaborates with Prof Rajendra Srivastava, Dean @ ISB, on digital disruptions and a book project. Marshall Goldsmith and he deliver ‘Leadership Thinking Nuggets’ series for Fortune. Besides corporate engagements, his most recent masterclass interventions have been with ET Masterclass, ISB workshops, TiE events, Industry Chamber and Ivy League engagements.

Piyush is an international keynote speaker and is sought out by the national and international media alike. His in-depth work as a certified mediation and Yoga teacher and as a master story-teller facilitate transformational leadership and capability building. Follow Piyush’s writings in Forbes and Fortune.

closepopup
Irina MeyerFounder and Managing Partner of Sils Capital Venture Fund

Irina Meyer is the founder of Sils Capital, a venture fund that invests internationally in early stage companies. Irina is a director, adviser and often majority stake investor in the fund's portfolio companies. Sils Capital commits to invest at least 50% of yearly rounds in women-led companies. 100% of the portfolio is impact investing, with 35% being in Life Science and Med Device ventures. Fluent in 6 languages, Irina is working with ventures in France, Germany, Switzerland, Israel, US and China. Irina's core expertise is in development and promotion of new technologies in digital media and interactive entertainment. She is an active member of the Academy of Television Arts and Sciences and the Emmys Foundation. Irina is a recipient of the 2011 Emmy for the Outstanding Achievement in Interactive Media

Irina MeyerFounder and Managing Partner of Sils Capital Venture Fund

Irina Meyer is the founder of Sils Capital, a venture fund that invests internationally in early stage companies. Irina is a director, adviser and often majority stake investor in the fund's portfolio companies. Sils Capital commits to invest at least 50% of yearly rounds in women-led companies. 100% of the portfolio is impact investing, with 35% being in Life Science and Med Device ventures. Fluent in 6 languages, Irina is working with ventures in France, Germany, Switzerland, Israel, US and China. Irina's core expertise is in development and promotion of new technologies in digital media and interactive entertainment. She is an active member of the Academy of Television Arts and Sciences and the Emmys Foundation. Irina is a recipient of the 2011 Emmy for the Outstanding Achievement in Interactive Media

closepopup
Tudor Oprea, M.D. Ph.D.Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine, University of New Mexico

Dr. Oprea has over two decades of knowledge and data mining in drug discovery, with focus on translational data science, cheminformatics, drug discovery & repurposing and virtual screening. Fifteen years of conceptual development for chemical space exploration, including leadlike and druglike properties for high-throughput screening and synthesis. Strong biomedical background with previous clinical and pharmaco-physiological training. Excellent communication and interpersonal skills. One book as editor (Wiley-VCH), one as author (on molecular modeling; in Romanian), twenty-four book chapters, five granted US patents, three pending patent applications, and over 160 peer-reviewed papers published since 1993.

Tudor Oprea, M.D. Ph.D.Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine, University of New Mexico

Dr. Oprea has over two decades of knowledge and data mining in drug discovery, with focus on translational data science, cheminformatics, drug discovery & repurposing and virtual screening. Fifteen years of conceptual development for chemical space exploration, including leadlike and druglike properties for high-throughput screening and synthesis. Strong biomedical background with previous clinical and pharmaco-physiological training. Excellent communication and interpersonal skills. One book as editor (Wiley-VCH), one as author (on molecular modeling; in Romanian), twenty-four book chapters, five granted US patents, three pending patent applications, and over 160 peer-reviewed papers published since 1993.

closepopup
Sumeet Bhatia, MD, MBBSPresident, Community Hospital Oncology Physicians

Dr. Bhatia is board certified in medical oncology, hematology and internal medicine by the American Board of Internal Medicine. He graduated from the University of Bombay Medical College, Bombay, India, and completed his residency in internal medicine at the University of Connecticut School of Medicine, Farmington, with a fellowship in hematology/oncology at the Indiana University School of Medicine, Indianapolis. He is a member of the American Society of Clinical Oncology and the Indiana State Medical Association.

Sumeet Bhatia, MD, MBBSPresident, Community Hospital Oncology Physicians

Dr. Bhatia is board certified in medical oncology, hematology and internal medicine by the American Board of Internal Medicine. He graduated from the University of Bombay Medical College, Bombay, India, and completed his residency in internal medicine at the University of Connecticut School of Medicine, Farmington, with a fellowship in hematology/oncology at the Indiana University School of Medicine, Indianapolis. He is a member of the American Society of Clinical Oncology and the Indiana State Medical Association.

closepopup
Kamala K Maddali DVM Ph.D.President, Health Collaborations and VP, Deep Lens

Dr. Maddali’s mantra for leadership is to “spread some sunshine” by being passionate and positive about her commitment to patient’s health through her collaborative mindset in precision/personalized medicine. Dr. Maddali is very committed to save lives, to empower those affected by cancer, and to inspire younger generations to stay committed to healthcare education and be the future of global community health. Dr. Maddali’s cross collaborative mindset comes from my unique healthcare professional background and education. She holds a Ph.D. in Pharmacology from the University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali is a native of Andhra Pradesh, India. While at Merck, Dr. Maddali played a pivotal role as a biomarker scientists understanding the various pharmacological and toxic effects of investigational drugs across multiple therapeutic areas in oncology, neurology and obesity disorders. She also has extensive experience as a chief scientific commercial liaison for precision medicine at top-tier central laboratories and reference laboratories, including Quintiles and Quest Diagnostics.

Kamala K Maddali DVM Ph.D.President, Health Collaborations and VP, Deep Lens

Dr. Maddali’s mantra for leadership is to “spread some sunshine” by being passionate and positive about her commitment to patient’s health through her collaborative mindset in precision/personalized medicine. Dr. Maddali is very committed to save lives, to empower those affected by cancer, and to inspire younger generations to stay committed to healthcare education and be the future of global community health. Dr. Maddali’s cross collaborative mindset comes from my unique healthcare professional background and education. She holds a Ph.D. in Pharmacology from the University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali is a native of Andhra Pradesh, India. While at Merck, Dr. Maddali played a pivotal role as a biomarker scientists understanding the various pharmacological and toxic effects of investigational drugs across multiple therapeutic areas in oncology, neurology and obesity disorders. She also has extensive experience as a chief scientific commercial liaison for precision medicine at top-tier central laboratories and reference laboratories, including Quintiles and Quest Diagnostics.

closepopup
Marcin von Grotthuss, PhDPrincipal Scientist, Takeda

Senior Computational Scientist with 18 years of experiences in developing sophisticated, analytical, bioinformatics algorithms, pipelines, and portals as well as applying them to understand complex biological data.

Credo: the properly conducted analysis of combined clinical, molecular and genomic data can be easily translated into clinical applications to increase a success rate of drug developments and to provide personalized medicine solution to patients.

Marcin von Grotthuss, PhDPrincipal Scientist, Takeda

Senior Computational Scientist with 18 years of experiences in developing sophisticated, analytical, bioinformatics algorithms, pipelines, and portals as well as applying them to understand complex biological data.

Credo: the properly conducted analysis of combined clinical, molecular and genomic data can be easily translated into clinical applications to increase a success rate of drug developments and to provide personalized medicine solution to patients.

closepopup
Piyush Mathur, MD.Founder, BrainX, Anesthesiologist/ Intensivist, Cleveland Clinic

Dr. Mathur is an anesthesiologist/Intensivist at Cleveland Clinic with greater than 20 years clinician experience.Also,trained in Quality through Cleveland Clinic quality fellowship with over 9 years of work experience as the Quality Improvement Officer of Anesthesiology Institute,Cleveland Clinic.For 9 years have also led the Compliance committee,Anesthesiology Institute,Cleveland Clinic.
As an educator, have chaired the postgraduate education committee,Society of Critical Care Medicine.For more than 2 years served as the Program Director,Anesthesiology Critical Care Fellowship program.
FCCM,Fellow of American College of Critical Care Medicine(SCCM).
Co-founder of BrainX and BrainX Community.
Recognized with more than 4 innovation awards at Cleveland Clinic,developer of difficult airway icon and process for EPIC.Trained in Computer programming through Udacity Nanodegree program with elective in data analysis, machine learning and artificial intelligence.

Piyush Mathur, MD.Founder, BrainX, Anesthesiologist/ Intensivist, Cleveland Clinic

Dr. Mathur is an anesthesiologist/Intensivist at Cleveland Clinic with greater than 20 years clinician experience.Also,trained in Quality through Cleveland Clinic quality fellowship with over 9 years of work experience as the Quality Improvement Officer of Anesthesiology Institute,Cleveland Clinic.For 9 years have also led the Compliance committee,Anesthesiology Institute,Cleveland Clinic.
As an educator, have chaired the postgraduate education committee,Society of Critical Care Medicine.For more than 2 years served as the Program Director,Anesthesiology Critical Care Fellowship program.
FCCM,Fellow of American College of Critical Care Medicine(SCCM).
Co-founder of BrainX and BrainX Community.
Recognized with more than 4 innovation awards at Cleveland Clinic,developer of difficult airway icon and process for EPIC.Trained in Computer programming through Udacity Nanodegree program with elective in data analysis, machine learning and artificial intelligence.

closepopup
Nazneen Aziz, Ph.D.CSO at Avellino Lab

Nazneen Aziz is CSO at Avellino Lab. She was the former Executive Director of the Kaiser Permanente Research Bank (KPRB). Where she was responsible for strategic direction and operations of KPRB. Her pervious roles, Dr. Aziz was the SVP and Chief Research Officer at Phoenix Children’s Hospital, Director of Molecular Medicine at the College of American Pathologists (CAP). During her tenure at CAP, she led the development of the first set of standards and proficiency tests for clinical laboratories using next-generation sequencing. Dr. Aziz held executive leadership positions in the biotech/biopharma industry where she focused on personalized medicine, genetic tests, and development of drugs for cancer and diabetes. In her academic career, Dr. Aziz was an Assistant Professor at Harvard Medical School and Boston Children’s Hospital. Dr. Aziz received her Ph.D. (molecular genetics) and MS (biochemistry) at MIT. Her publications have been cited extensively in the medical and scientific literature and she has been invited to speak at numerous national and international conferences.

Nazneen Aziz, Ph.D.CSO at Avellino Lab

Nazneen Aziz is CSO at Avellino Lab. She was the former Executive Director of the Kaiser Permanente Research Bank (KPRB). Where she was responsible for strategic direction and operations of KPRB. Her pervious roles, Dr. Aziz was the SVP and Chief Research Officer at Phoenix Children’s Hospital, Director of Molecular Medicine at the College of American Pathologists (CAP). During her tenure at CAP, she led the development of the first set of standards and proficiency tests for clinical laboratories using next-generation sequencing. Dr. Aziz held executive leadership positions in the biotech/biopharma industry where she focused on personalized medicine, genetic tests, and development of drugs for cancer and diabetes. In her academic career, Dr. Aziz was an Assistant Professor at Harvard Medical School and Boston Children’s Hospital. Dr. Aziz received her Ph.D. (molecular genetics) and MS (biochemistry) at MIT. Her publications have been cited extensively in the medical and scientific literature and she has been invited to speak at numerous national and international conferences.

closepopup
Ron Lanton III, J.D., EsqPrincipal Lanton Law, Chair, Biologics Committee, New York State Bar Association

Ron Lanton III, Esq., has over 25 years of experience focused on legal and government affairs which includes activities on the municipal, state, and federal government levels with 15 years dedicated to the healthcare sector. Ron is currently the Principal at Lanton Law and President of Lanton Strategies.

Prior to his new ventures, Ron served as the Executive Director at Frier Levitt Government Affairs and also served as Senior Counsel for Frier Levitt law. He previously founded True North Political Solutions, worked at a pharmaceutical wholealer where he served as the company’s exclusive lobbyist and also advocated for the company's various healthcare customers which included retail and specialty pharmacy, institutional and HME.

He has also worked Stateside Associates, a greater Washington D.C. area government affairs consulting firm consulting telecommunications, energy, transportation and healthcare clients.

Ron has clerked for a federal magistrate, was appointed as a municipal commissioner and frequently consults Wall Street firms on financial issues related to the healthcare sector.

Ron is a featured industry speaker on issues such as pharmaceutical safety and healthcare cost containment and is a regular contributor to Specialty Pharmacy Times, Biosimilar Development and the Center for Biosimilars.

Ron is the chair of the Biologics Committee for the New York Bar Association and is currently admitted to practice in Illinois, Washington D.C. and New York.

Mr. Lanton has a Juris Doctor from The Ohio State University Moritz College of Law and a Bachelor of Arts from Miami University of Ohio. He is also a 40 under 40 award recipient.

Ron Lanton III, J.D., EsqPrincipal Lanton Law, Chair, Biologics Committee, New York State Bar Association

Ron Lanton III, Esq., has over 25 years of experience focused on legal and government affairs which includes activities on the municipal, state, and federal government levels with 15 years dedicated to the healthcare sector. Ron is currently the Principal at Lanton Law and President of Lanton Strategies.

Prior to his new ventures, Ron served as the Executive Director at Frier Levitt Government Affairs and also served as Senior Counsel for Frier Levitt law. He previously founded True North Political Solutions, worked at a pharmaceutical wholealer where he served as the company’s exclusive lobbyist and also advocated for the company's various healthcare customers which included retail and specialty pharmacy, institutional and HME.

He has also worked Stateside Associates, a greater Washington D.C. area government affairs consulting firm consulting telecommunications, energy, transportation and healthcare clients.

Ron has clerked for a federal magistrate, was appointed as a municipal commissioner and frequently consults Wall Street firms on financial issues related to the healthcare sector.

Ron is a featured industry speaker on issues such as pharmaceutical safety and healthcare cost containment and is a regular contributor to Specialty Pharmacy Times, Biosimilar Development and the Center for Biosimilars.

Ron is the chair of the Biologics Committee for the New York Bar Association and is currently admitted to practice in Illinois, Washington D.C. and New York.

Mr. Lanton has a Juris Doctor from The Ohio State University Moritz College of Law and a Bachelor of Arts from Miami University of Ohio. He is also a 40 under 40 award recipient.

closepopup
Daniel J. Mueller, MD, Ph.D.Professor, University of Toronto

Dr. Mueller is Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to implement pharmacogenetics in clinical practice for antidepressant and antipsychotic medications. Dr. Mueller is actively involved in developing pharmacogenetics treatment recommendations for physicians and patients through his close collaboration with international organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the International Society of Psychiatric Genetics (ISPG) and the Pharmacogenetics Research Network (PGRN).

Daniel J. Mueller, MD, Ph.D.Professor, University of Toronto

Dr. Mueller is Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to implement pharmacogenetics in clinical practice for antidepressant and antipsychotic medications. Dr. Mueller is actively involved in developing pharmacogenetics treatment recommendations for physicians and patients through his close collaboration with international organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the International Society of Psychiatric Genetics (ISPG) and the Pharmacogenetics Research Network (PGRN).

closepopup
Jay ChenPartner, Hope Venture Labs

Jay Chen is partner at Hope Venture Labs. He is passionate about social and technological innovations that impact health and the environment. Jay is a veteran VC in silicon valley and is a five -time producer of US/China Technology CEO Summit and Annual Conference. Jay also serves as a co-chair of the AAPM Coronavirus Taskforce (ACT).

Jay ChenPartner, Hope Venture Labs

Jay Chen is partner at Hope Venture Labs. He is passionate about social and technological innovations that impact health and the environment. Jay is a veteran VC in silicon valley and is a five -time producer of US/China Technology CEO Summit and Annual Conference. Jay also serves as a co-chair of the AAPM Coronavirus Taskforce (ACT).

closepopup
Kristine Ashcraft, MBAHead of Pharmacogenomics, Invitae, Former CEO, YouScript

Kristine Ashcraft, is head of pharmacogenomics, Invitae and former CEO of YouScript, a spin-out from Genelex Corporation. She has worked in the precision medicine space since 2000. Kristine has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications of 2015 at a recent AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at SXSW, ASHG, and numerous Precision Medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.

Kristine Ashcraft, MBAHead of Pharmacogenomics, Invitae, Former CEO, YouScript

Kristine Ashcraft, is head of pharmacogenomics, Invitae and former CEO of YouScript, a spin-out from Genelex Corporation. She has worked in the precision medicine space since 2000. Kristine has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications of 2015 at a recent AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at SXSW, ASHG, and numerous Precision Medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.

closepopup
Santhosh BalasubramanianDirector, Notable Labs

Santhosh Balasubramanian is the Director of Product at Notable Labs, where he leads a team developing predictive clinical diagnostics for blood cancers. Prior to Notable Labs, Santhosh held roles as a biomedical informatics researcher at Stanford School of Medicine and a product manager at Khan Academy and Google. Throughout his career, Santhosh has been passionate about designing and building technology to help people learn, heal, and grow. Santhosh studied computer science and biology at Princeton University.

Santhosh BalasubramanianDirector, Notable Labs

Santhosh Balasubramanian is the Director of Product at Notable Labs, where he leads a team developing predictive clinical diagnostics for blood cancers. Prior to Notable Labs, Santhosh held roles as a biomedical informatics researcher at Stanford School of Medicine and a product manager at Khan Academy and Google. Throughout his career, Santhosh has been passionate about designing and building technology to help people learn, heal, and grow. Santhosh studied computer science and biology at Princeton University.

closepopup
Reem MahratFounder and CEO Calico BioLabs, Director AAPM

Reem Mahrat is founder and CEO at Calico Biolabs, where she leads scientific operations, and negotiated toward the eventual acquisition of Calico to Abcam in January of 2019. Calico developed antibodies against novel cancer bio-markers for its Pharma and diagnostic customers. Reem has a successful track record of clinical research with over 19 years’ experience in the Drug discovery industry, primarily supporting Ab discovery for use in diagnostics by the pharmaceutical and biotechnology sectors. With a background in Chemical Engineering, Reem had developed novel technologies, mainly focusing on biomarker development and discovery for cancer diagnostics. Prior to Calico, Reem supported the Research team at Roche and Co-developed a number of methodologies and products including novel recombinant monoclonal chicken anti-rabbit and chicken anti-mouse antibodies. Reem is a director of the American Association for Precision Medicine and an active member of of the top research, health care, and disease advocacy organizations.

Reem MahratFounder and CEO Calico BioLabs, Director AAPM

Reem Mahrat is founder and CEO at Calico Biolabs, where she leads scientific operations, and negotiated toward the eventual acquisition of Calico to Abcam in January of 2019. Calico developed antibodies against novel cancer bio-markers for its Pharma and diagnostic customers. Reem has a successful track record of clinical research with over 19 years’ experience in the Drug discovery industry, primarily supporting Ab discovery for use in diagnostics by the pharmaceutical and biotechnology sectors. With a background in Chemical Engineering, Reem had developed novel technologies, mainly focusing on biomarker development and discovery for cancer diagnostics. Prior to Calico, Reem supported the Research team at Roche and Co-developed a number of methodologies and products including novel recombinant monoclonal chicken anti-rabbit and chicken anti-mouse antibodies. Reem is a director of the American Association for Precision Medicine and an active member of of the top research, health care, and disease advocacy organizations.

closepopup
Suraj Saksena, Ph.D.Science, and Technology Leader, BD

Suraj Saksena, PhD is a team Lead/Senior Scientist: 14 years of experience in conducting scientific research including 3 years of experience working in drug discovery and 2 years of experience working in medical diagnostics in the Biotech industry. He has an excellent track record of obtaining scientific funding for conducting research. He is highly accomplished scientist with an excellent track record of obtaining research funding and mentoring junior scientists. He is an author of 14 peer-reviewed publications in top-rated scientific journals. PhD in Biochemistry from Texas A&M University.

Suraj Saksena, Ph.D.Science, and Technology Leader, BD

Suraj Saksena, PhD is a team Lead/Senior Scientist: 14 years of experience in conducting scientific research including 3 years of experience working in drug discovery and 2 years of experience working in medical diagnostics in the Biotech industry. He has an excellent track record of obtaining scientific funding for conducting research. He is highly accomplished scientist with an excellent track record of obtaining research funding and mentoring junior scientists. He is an author of 14 peer-reviewed publications in top-rated scientific journals. PhD in Biochemistry from Texas A&M University.

closepopup
Sanjit Singh Dang, PhDCo-founder, Chairman, U First Capital, Ex-IntelCapital VC

Sanjit has been a successful Venture Capitalist, Corporate Executive, Board Member, Speaker and Writer in Silicon Valley for almost two decades. He is currently the Co-Founder and Chairman of U First Capital which provides Venture Capital as a Service to Corporations. Prior to that, he was at Intel Capital where he had an excellent track record of driving 1 Exit every year: Palantir (IPO 2020), Orb Intelligence (Acquired by Dun and Bradstreet in 2020), Pinterest (IPO 2019), DocuSign (IPO 2018), Body Labs (Acquired by Amazon in 2017), VokeVR (Acquired by Intel in 2016), Maginatics (Acquired by EMC in 2015) and Basis Science (Acquired by Intel in 2014). He has been an Investor and Board Member of several companies, including True Fit (AI for eCommerce, raised $100M), Reflektion (AI recommendation for eCommerce, raised $42M), Helpshift (AI-driven Customer Service, raised $39M) and Enlighted (IoT, Acquired by Siemens in 2018). He is also an investor in Mirantis (Cloud Computing), GoodData (SaaS BI) and Arcadia Data (Big Data 2.0).

Sanjit has experience investing in Consumer and Enterprise sectors across several areas: Transportation, Artificial Intelligence, Security, Big Data, IoT, Virtual Reality, eCommerce, etc.

Sanjit has been an Advisor to Richard Branson’s Extreme Tech Challenge and Google Launchpad. Sanjit has been on US Govt Innovation Policy Advisory team. He is on Advisory Council of UN’s World Artificial Intelligence Organization. He has also been on University of California President's Innovation Council. Sanjit has the fastest Eng PhD from University of Illinois (2yrs 9mo after undergrad), which he received in 2000 with top research awards. He also attended the VC Executive program at Haas School of Business, UC Berkeley. He’s an invited Speaker at several top conferences, eg SURGE/WebSummit, TiECon, ShopTalk, McKinsey Leadership Summit, Silicon Valley Open Doors, Global AI conference, etc. He’s a mentor at Stanford and Berkeley’s Entrepreneurship programs.

Sanjit Singh Dang, PhDCo-founder, Chairman, U First Capital, Ex-IntelCapital VC

Sanjit has been a successful Venture Capitalist, Corporate Executive, Board Member, Speaker and Writer in Silicon Valley for almost two decades. He is currently the Co-Founder and Chairman of U First Capital which provides Venture Capital as a Service to Corporations. Prior to that, he was at Intel Capital where he had an excellent track record of driving 1 Exit every year: Palantir (IPO 2020), Orb Intelligence (Acquired by Dun and Bradstreet in 2020), Pinterest (IPO 2019), DocuSign (IPO 2018), Body Labs (Acquired by Amazon in 2017), VokeVR (Acquired by Intel in 2016), Maginatics (Acquired by EMC in 2015) and Basis Science (Acquired by Intel in 2014). He has been an Investor and Board Member of several companies, including True Fit (AI for eCommerce, raised $100M), Reflektion (AI recommendation for eCommerce, raised $42M), Helpshift (AI-driven Customer Service, raised $39M) and Enlighted (IoT, Acquired by Siemens in 2018). He is also an investor in Mirantis (Cloud Computing), GoodData (SaaS BI) and Arcadia Data (Big Data 2.0).

Sanjit has experience investing in Consumer and Enterprise sectors across several areas: Transportation, Artificial Intelligence, Security, Big Data, IoT, Virtual Reality, eCommerce, etc.

Sanjit has been an Advisor to Richard Branson’s Extreme Tech Challenge and Google Launchpad. Sanjit has been on US Govt Innovation Policy Advisory team. He is on Advisory Council of UN’s World Artificial Intelligence Organization. He has also been on University of California President's Innovation Council. Sanjit has the fastest Eng PhD from University of Illinois (2yrs 9mo after undergrad), which he received in 2000 with top research awards. He also attended the VC Executive program at Haas School of Business, UC Berkeley. He’s an invited Speaker at several top conferences, eg SURGE/WebSummit, TiECon, ShopTalk, McKinsey Leadership Summit, Silicon Valley Open Doors, Global AI conference, etc. He’s a mentor at Stanford and Berkeley’s Entrepreneurship programs.

closepopup
Sanket Mishra, MPharma, MS, PhDCo-founder Grannus Therapeutics

Sanket Mishra, MPharma, MS, PhD, is a Co-founder and Chief Scientific Officer at Grannus Therapeutics. Grannus is developing of safer anticancer medicines by inhibiting Hsp90 isoforms. Dr. Mishra received his PhD from Kansas University and a postdoctoral fellowship at the University of Notre Dame and has a broad knowledge of pharmaceutics, chemistry, pharmacology, biochemistry and computational techniques. Dr, Mishra has over 10 years of experience in the pharmaceuticals and medicinal chemistry, and a proven track record of driving the advancement of drug discovery programs. His goal is to contribute and/or invent novel medicines by applying innovative synthetic chemistry, analytical techniques and data analysis to design and synthesize drug candidates and intermediates. Over the years, he has acquired experimental and theoretical knowledge of formulation sciences, pharmacology, biochemistry, pharmacognosy, anatomy, pathophysiology, physical and analytical chemistry, microbiology and biotechnology. He has discovered multiple first-in-class isoform-selective Hsp90 inhibitory scaffolds using a structure-based drug design approach that will lead to safer anti-cancer drugs. Furthermore, he has contributed to multiple publications, presentations and patents (three patents filed for the discovered isoform-selective Hsp90 inhibitor scaffolds with a few more in preparation). Over the years, he has provided scientific mentoring and technical training to several scientists and has been instrumental His expertise includes, basic analytical and structural data analysis and trouble-shooting synthetic routes to target molecules. Dr. Mishra has contributed in drug discovery for many therapeutic areas and has been instrumental is driving collaborations with thought leaders and KOLs.

Sanket Mishra, MPharma, MS, PhDCo-founder Grannus Therapeutics

Sanket Mishra, MPharma, MS, PhD, is a Co-founder and Chief Scientific Officer at Grannus Therapeutics. Grannus is developing of safer anticancer medicines by inhibiting Hsp90 isoforms. Dr. Mishra received his PhD from Kansas University and a postdoctoral fellowship at the University of Notre Dame and has a broad knowledge of pharmaceutics, chemistry, pharmacology, biochemistry and computational techniques. Dr, Mishra has over 10 years of experience in the pharmaceuticals and medicinal chemistry, and a proven track record of driving the advancement of drug discovery programs. His goal is to contribute and/or invent novel medicines by applying innovative synthetic chemistry, analytical techniques and data analysis to design and synthesize drug candidates and intermediates. Over the years, he has acquired experimental and theoretical knowledge of formulation sciences, pharmacology, biochemistry, pharmacognosy, anatomy, pathophysiology, physical and analytical chemistry, microbiology and biotechnology. He has discovered multiple first-in-class isoform-selective Hsp90 inhibitory scaffolds using a structure-based drug design approach that will lead to safer anti-cancer drugs. Furthermore, he has contributed to multiple publications, presentations and patents (three patents filed for the discovered isoform-selective Hsp90 inhibitor scaffolds with a few more in preparation). Over the years, he has provided scientific mentoring and technical training to several scientists and has been instrumental His expertise includes, basic analytical and structural data analysis and trouble-shooting synthetic routes to target molecules. Dr. Mishra has contributed in drug discovery for many therapeutic areas and has been instrumental is driving collaborations with thought leaders and KOLs.

closepopup
Linda Ellison, Ph.D.Founder and CEO of kaü Health, Former Managing Director, United Nations

Dr. Linda Ellison earned her doctorate at Harvard University and is an expert on the impact of concentrated, complete and optimized amino acids on immunity for individual and population health. As one of the Public Health Systems Managing Directors at the United Nations, West Africa Region, Dr. Linda directly addressed the impact of nutritional deficiencies, specifically amino acids, on maternal malaria (endemic in the region) as part of the UN's Millennium Development Goals (MDG). Prior to her role at the United Nations, Dr. Linda taught courses at Harvard College in History of Science, Economics, Anthropology, and Women, Gender, & Sexuality including The Economics of Epidemics, The Economics of Malnutrition, The Economics of Maternal Medicine, and The Economics of Disease and Wellness in a Global Social Context. Dr. Linda inherited several "remedy recipes" from her folk-healer grandmother, and optimized them with extensive scientific research and laboratory testing together with a small team of other Harvard-trained Scientists. During the course of this research and development, she created a biotechnology company that offers products to hospitals and consumers, kaü Health. IMMUNITY BUILD, a concentrated, complete and optimized set of amino acids that helps trigger new, robust immune system cell generation is kaü's first product.

Linda Ellison, Ph.D.Founder and CEO of kaü Health, Former Managing Director, United Nations

Dr. Linda Ellison earned her doctorate at Harvard University and is an expert on the impact of concentrated, complete and optimized amino acids on immunity for individual and population health. As one of the Public Health Systems Managing Directors at the United Nations, West Africa Region, Dr. Linda directly addressed the impact of nutritional deficiencies, specifically amino acids, on maternal malaria (endemic in the region) as part of the UN's Millennium Development Goals (MDG). Prior to her role at the United Nations, Dr. Linda taught courses at Harvard College in History of Science, Economics, Anthropology, and Women, Gender, & Sexuality including The Economics of Epidemics, The Economics of Malnutrition, The Economics of Maternal Medicine, and The Economics of Disease and Wellness in a Global Social Context. Dr. Linda inherited several "remedy recipes" from her folk-healer grandmother, and optimized them with extensive scientific research and laboratory testing together with a small team of other Harvard-trained Scientists. During the course of this research and development, she created a biotechnology company that offers products to hospitals and consumers, kaü Health. IMMUNITY BUILD, a concentrated, complete and optimized set of amino acids that helps trigger new, robust immune system cell generation is kaü's first product.

closepopup
Amit BansalFounder, CEO at Diya Health Inc.

Amit is an experienced software engineer who has led large organizations that develop and deploy SaaS products. His record of achievements includes innovations, expansion, and profitability. As CEO, Amit serves as the company’s lead communicatory, fundraiser, and talent recruiter. Amit directs the company’s efforts to achieve a clear vision of healthcare system improvement.

Amit BansalFounder, CEO at Diya Health Inc.

Amit is an experienced software engineer who has led large organizations that develop and deploy SaaS products. His record of achievements includes innovations, expansion, and profitability. As CEO, Amit serves as the company’s lead communicatory, fundraiser, and talent recruiter. Amit directs the company’s efforts to achieve a clear vision of healthcare system improvement.

closepopup
Darwin LingFounder and General Partner at Good AI Capital

Darwin Ling is the founding general partner of Good AI Capital, a mission-driven venture fund focusing on early-stage AI companies in Fintech, Healthcare, and B2B SaaS. Prior to that, he has been an entrepreneur with multiple exits, a technologist as well as an angel investor in successful unicorns such as SoFi .

Most recently, Darwin served as the CTO and co-founder of SmarterMe, which aims to improve sales productivity by bringing AI / Intelligence to the flow of work. Counting enterprise customers such as Danaher ( Fortune 500 medical device ), Home Depot and GE, SmarterMe was recently acquired. As a distinguished alumnus of Purdue University, Darwin was featured as one of Purdue’s Tech Titans and is serving on the leadership council for the School of Science

Darwin received his MBA (Honors) from the University of Chicago Booth School of Business. He also holds a BS ( Phi Beta Kappa ) with distinction in Computer Science and Mathematics and an MS in Computer Science, both from Purdue University.

Darwin LingFounder and General Partner at Good AI Capital

Darwin Ling is the founding general partner of Good AI Capital, a mission-driven venture fund focusing on early-stage AI companies in Fintech, Healthcare, and B2B SaaS. Prior to that, he has been an entrepreneur with multiple exits, a technologist as well as an angel investor in successful unicorns such as SoFi .

Most recently, Darwin served as the CTO and co-founder of SmarterMe, which aims to improve sales productivity by bringing AI / Intelligence to the flow of work. Counting enterprise customers such as Danaher ( Fortune 500 medical device ), Home Depot and GE, SmarterMe was recently acquired. As a distinguished alumnus of Purdue University, Darwin was featured as one of Purdue’s Tech Titans and is serving on the leadership council for the School of Science

Darwin received his MBA (Honors) from the University of Chicago Booth School of Business. He also holds a BS ( Phi Beta Kappa ) with distinction in Computer Science and Mathematics and an MS in Computer Science, both from Purdue University.

closepopup
Mohan UttarwarFounder and CEO, INDEX.AI

Mohan Uttarwar is the co-founder and CEO of iNDX.AI, a silicon valley based Healthcare Informatics Company focusing on Translation Research in Oncology using AI/ML/NLP technologies. He is a serial entrepreneur with over 30 years of experience in successfully founding, establishing and exiting high-tech and Biotech start-ups in Silicon Valley, raising over $50M in funding and generating over $500M in shareholder value. He is an Angel Investor & serves on the BOD of Hemex Health, a very innovative point of care Malaria & Sickle cell Diagnostics Company. Mohan has joined Stanford University Medical School as a Research Scholar to work on developing new Socio-Economic business models that leverage innovation in affordable medical technology and transform the Health Care at the bottom of the pyramid in developing world, touching Billion Lives and creating Millions of jobs at the Micro & Macro levels. Mohan was the cofounder and CEO of iNDx LifeCare, next generation Point of Care Company, Oncomdx, an innovative Cancer Diagnostics company, which specialized, in integrated diagnostics (acquired by Core Diagnostics 2013). Mohan was the cofounder and CEO of BioImagene, a pioneer in Digital Pathology that was acquired by Roche in 2010 for $100M. He was the co-founder and CEO of Roamware Inc., a leading wireless roaming software company (acquired by Audax for $135M). He was also the cofounder and CEO of SoftPlus, an early provider of eCRM software for telecom carriers around the world. In March 2000, SoftPlus was sold to US Interactive for $360 million. Before starting SoftPlus, Mohan co-founded and served as the CEO of Digital Tools Inc., a leader in enterprise project and resource management software (Acquired by Toofan, Inc.). He previously held various software development and management positions with Hewlett Packard and Intel Corporation.
Mohan holds a Masters Degree in Computer Science from the Florida Institute of Technology and a Masters Degree in Electrical Engineering from Bombay University, and attended and advanced Management Program at Stanford University. He is a charter member of TiE (The Indus Entrepreneurs), a Silicon Valley-based forum for entrepreneurs. He is on the board of several non-profit organizations such as EPPIC: Association of Biotech and Pharma Executives; IDE - a leading non-profit devoted to the eradication of rural poverty worldwide; Drev – design revolution for the other 90% and DPA – Digital Pathology Association.
He lives in Cupertino California with his wife and 2 children, has run a marathon and Triathlon, is an avid trekker (trekked in all 7 continents, including Mt Kailash, Everest Base Camp (Himalayas), Kilimanjaro, Machu Picchu, Mont Blanc) and biked around Lake Tahoe (Tahoe Century) to help fund raising for cancer research.

Mohan UttarwarFounder and CEO, INDEX.AI

Mohan Uttarwar is the co-founder and CEO of iNDX.AI, a silicon valley based Healthcare Informatics Company focusing on Translation Research in Oncology using AI/ML/NLP technologies. He is a serial entrepreneur with over 30 years of experience in successfully founding, establishing and exiting high-tech and Biotech start-ups in Silicon Valley, raising over $50M in funding and generating over $500M in shareholder value. He is an Angel Investor & serves on the BOD of Hemex Health, a very innovative point of care Malaria & Sickle cell Diagnostics Company. Mohan has joined Stanford University Medical School as a Research Scholar to work on developing new Socio-Economic business models that leverage innovation in affordable medical technology and transform the Health Care at the bottom of the pyramid in developing world, touching Billion Lives and creating Millions of jobs at the Micro & Macro levels. Mohan was the cofounder and CEO of iNDx LifeCare, next generation Point of Care Company, Oncomdx, an innovative Cancer Diagnostics company, which specialized, in integrated diagnostics (acquired by Core Diagnostics 2013). Mohan was the cofounder and CEO of BioImagene, a pioneer in Digital Pathology that was acquired by Roche in 2010 for $100M. He was the co-founder and CEO of Roamware Inc., a leading wireless roaming software company (acquired by Audax for $135M). He was also the cofounder and CEO of SoftPlus, an early provider of eCRM software for telecom carriers around the world. In March 2000, SoftPlus was sold to US Interactive for $360 million. Before starting SoftPlus, Mohan co-founded and served as the CEO of Digital Tools Inc., a leader in enterprise project and resource management software (Acquired by Toofan, Inc.). He previously held various software development and management positions with Hewlett Packard and Intel Corporation.
Mohan holds a Masters Degree in Computer Science from the Florida Institute of Technology and a Masters Degree in Electrical Engineering from Bombay University, and attended and advanced Management Program at Stanford University. He is a charter member of TiE (The Indus Entrepreneurs), a Silicon Valley-based forum for entrepreneurs. He is on the board of several non-profit organizations such as EPPIC: Association of Biotech and Pharma Executives; IDE - a leading non-profit devoted to the eradication of rural poverty worldwide; Drev – design revolution for the other 90% and DPA – Digital Pathology Association.
He lives in Cupertino California with his wife and 2 children, has run a marathon and Triathlon, is an avid trekker (trekked in all 7 continents, including Mt Kailash, Everest Base Camp (Himalayas), Kilimanjaro, Machu Picchu, Mont Blanc) and biked around Lake Tahoe (Tahoe Century) to help fund raising for cancer research.

closepopup
Mat Chacon, MBACEO, Doghead Simulations

Mat Chacon is CEO of the award winning spatial computing company, Doghead Simulations, makers of the virtual reality education and training platform named rumii.

Growing up in poverty, Mat couldn’t afford college. So, he helped start a website development company in 1994. At 25, Mat took part in the $63 million USWeb IPO. By 35, he was a successful software startup executive and by 45 Mat was named a top 20 VR executive. Mat eventually attended college when he could afford it and completed studies in counterintelligence from American Military University, marketing from Rutgers Business School and studied mergers and acquisitions at Harvard Business School, in addition to holding multiple business process certificates. Mat now teaches online education using his VR platform, rumii, which won the global award for most innovative enterprise application at the annual VR/AR/XR executive conference produced by Greenlight Insights, which tracks global leaders in virtual and augmented reality.

Mat currently serves on the Human Dimensions Support Services Think Tank with the U.S. Department of Defense and advises the U.S. government on spatial computing technologies to improve human performance for current task orders and forward looking capabilities of today’s warfighter. Mat is also an active member of The American Association for Precision Medicine’s Coronavirus Task Force, a global think tank of scientists, doctors and thought leaders developing innovative solutions to the COVID-19 pandemic. Mat also recently helped invent and patent an immersive COVID-19 mental health therapy.

Mat has led his company to be a leader in immersive education and training and grown it by over of 400% year-over-year. Mat’s company is also highlighted in the PBS documentary Good All Over, showing how rumii is being used in global philanthropy to truly democratize education through spatial computing.

Virtual Reality is Mat’s passion, but education is his purpose. Mat co-founded Doghead Simulations to make education accessible & affordable to all.

In addition to his business accolades, Mat is also an accomplished photographer. He holds a degree in Photojournalism from the New York Institute of Photography and his work has been shown in Leica Fotografie International as well as at multiple gallery shows since 2017 and sold out at every event.

Mat Chacon, MBACEO, Doghead Simulations

Mat Chacon is CEO of the award winning spatial computing company, Doghead Simulations, makers of the virtual reality education and training platform named rumii.

Growing up in poverty, Mat couldn’t afford college. So, he helped start a website development company in 1994. At 25, Mat took part in the $63 million USWeb IPO. By 35, he was a successful software startup executive and by 45 Mat was named a top 20 VR executive. Mat eventually attended college when he could afford it and completed studies in counterintelligence from American Military University, marketing from Rutgers Business School and studied mergers and acquisitions at Harvard Business School, in addition to holding multiple business process certificates. Mat now teaches online education using his VR platform, rumii, which won the global award for most innovative enterprise application at the annual VR/AR/XR executive conference produced by Greenlight Insights, which tracks global leaders in virtual and augmented reality.

Mat currently serves on the Human Dimensions Support Services Think Tank with the U.S. Department of Defense and advises the U.S. government on spatial computing technologies to improve human performance for current task orders and forward looking capabilities of today’s warfighter. Mat is also an active member of The American Association for Precision Medicine’s Coronavirus Task Force, a global think tank of scientists, doctors and thought leaders developing innovative solutions to the COVID-19 pandemic. Mat also recently helped invent and patent an immersive COVID-19 mental health therapy.

Mat has led his company to be a leader in immersive education and training and grown it by over of 400% year-over-year. Mat’s company is also highlighted in the PBS documentary Good All Over, showing how rumii is being used in global philanthropy to truly democratize education through spatial computing.

Virtual Reality is Mat’s passion, but education is his purpose. Mat co-founded Doghead Simulations to make education accessible & affordable to all.

In addition to his business accolades, Mat is also an accomplished photographer. He holds a degree in Photojournalism from the New York Institute of Photography and his work has been shown in Leica Fotografie International as well as at multiple gallery shows since 2017 and sold out at every event.

closepopup
Tatyana Kanzaveli, MSFounder and CEO of Open Health Network

Tatyana Kanzaveli has gone from a programmer to senior executive at Big 5 to founder and CEO of a startup company along her 20 year career,recognized as a thought leader, mentor for her ability to guide Fortune 500 and startup companies through business challenges.
She’s worked for major companies like PricewaterhouseCoopers and Fujitsu and startups in the early days of the Web.
Tatyana has personally helped companies jump from 0 to millions in revenue even during the toughest economic times. She opened new verticals and markets.
Today she is the founder and CEO of Open Health Network, the startup in a Big Data/Healthcare space. She is a mentor at 500Startups and Richard Branson Entrepreneurs Centre and serves on boards for private companies. She also is licensee and organizer of highly notable TEDxBayArea conferences, she is a frequent speaker at US and International conferences on innovation, entrepreneurship and digital health.
Tatyana has been featured in the White House blog , spoke at the United Nations, presented at the first White House Demo Day hosted by the President Obama.
Tatyana has been recognized as one of the top 10 Influential Women in Healthcare IT in 2015.
Tatyana was USSR chess champion, played in the same team with Gary Kasparov, she loves to cook and kayak.

Tatyana Kanzaveli, MSFounder and CEO of Open Health Network

Tatyana Kanzaveli has gone from a programmer to senior executive at Big 5 to founder and CEO of a startup company along her 20 year career,recognized as a thought leader, mentor for her ability to guide Fortune 500 and startup companies through business challenges.
She’s worked for major companies like PricewaterhouseCoopers and Fujitsu and startups in the early days of the Web.
Tatyana has personally helped companies jump from 0 to millions in revenue even during the toughest economic times. She opened new verticals and markets.
Today she is the founder and CEO of Open Health Network, the startup in a Big Data/Healthcare space. She is a mentor at 500Startups and Richard Branson Entrepreneurs Centre and serves on boards for private companies. She also is licensee and organizer of highly notable TEDxBayArea conferences, she is a frequent speaker at US and International conferences on innovation, entrepreneurship and digital health.
Tatyana has been featured in the White House blog , spoke at the United Nations, presented at the first White House Demo Day hosted by the President Obama.
Tatyana has been recognized as one of the top 10 Influential Women in Healthcare IT in 2015.
Tatyana was USSR chess champion, played in the same team with Gary Kasparov, she loves to cook and kayak.

closepopup
Hunter WhitneySr. Director, UX at RiskIQ, Author of Data Insights, and Instructor, UC Berkeley Ext.

I am a design strategist, instructor, and author who brings a distinct UX design perspective to data visualization and analytics. I have advised corporations, start-ups, government agencies, and NGOs to help them achieve their goals through a thoughtful, strategic design approach to digital products and services.

I am also a writer and the author of "Data Insights: New Ways to Visualize and Make Sense of Data”. Additionally, I was asked to contribute a chapter in the book, “Designing for Emerging Technologies: UX for Genomics, Robotics, and the Internet of Things”. Other writing experience includes copywriting and numerous articles covering a range of subjects for various online and print publications.

My teaching experience includes being a classroom instructor for the courses - "Design Thinking and UX Strategy" and "Human-Centered Design for Data Visualization" for UC Berkeley Extension. I am also an instructor and curriculum advisor for data visualization and UX design programs with UC Davis on Coursera. In addition, I'm a guest lecturer for Northeastern University’s Level Analytics Bootcamps.

Hunter WhitneySr. Director, UX at RiskIQ, Author of Data Insights, and Instructor, UC Berkeley Ext.

I am a design strategist, instructor, and author who brings a distinct UX design perspective to data visualization and analytics. I have advised corporations, start-ups, government agencies, and NGOs to help them achieve their goals through a thoughtful, strategic design approach to digital products and services.

I am also a writer and the author of "Data Insights: New Ways to Visualize and Make Sense of Data”. Additionally, I was asked to contribute a chapter in the book, “Designing for Emerging Technologies: UX for Genomics, Robotics, and the Internet of Things”. Other writing experience includes copywriting and numerous articles covering a range of subjects for various online and print publications.

My teaching experience includes being a classroom instructor for the courses - "Design Thinking and UX Strategy" and "Human-Centered Design for Data Visualization" for UC Berkeley Extension. I am also an instructor and curriculum advisor for data visualization and UX design programs with UC Davis on Coursera. In addition, I'm a guest lecturer for Northeastern University’s Level Analytics Bootcamps.

closepopup
Mark Rees, Ph.D.SVP R&D and Innovations StatLab

Mark Rees is an experienced Scientific Affairs and Business Development Consultant with a broad knowledge of many disciplines within the clinical diagnostic markets.

He is a specialist in commercial execution for diagnostics; through concept to launch, driving sales success.

He has proven networking ability building multiple collaborative relationships with Key Opinion Leading clinicians at Premier Medical & Academic Centers across the US.

He is dedicated to success and a high level of performance, utilizing strong leadership and management skills to regularly exceed goals in both diagnostic and research markets.

Mark Rees, Ph.D.SVP R&D and Innovations StatLab

Mark Rees is an experienced Scientific Affairs and Business Development Consultant with a broad knowledge of many disciplines within the clinical diagnostic markets.

He is a specialist in commercial execution for diagnostics; through concept to launch, driving sales success.

He has proven networking ability building multiple collaborative relationships with Key Opinion Leading clinicians at Premier Medical & Academic Centers across the US.

He is dedicated to success and a high level of performance, utilizing strong leadership and management skills to regularly exceed goals in both diagnostic and research markets.

closepopup
Nivedita Lakhera, MDInternal Medicine - Hospitalist, and Author

Dr. Nivedita Lakhera is an internist in San Jose, CA and is affiliated with multiple hospitals in the area, including Community Regional Medical Center, El Camino Hospital, and Regional Medical Center of San Jose. She received her medical degree from TD Medical College Kerala and has been in practice 16 years. She specializes in hospital medicine/hospitalist.

Nivedita Lakhera, MDInternal Medicine - Hospitalist, and Author

Dr. Nivedita Lakhera is an internist in San Jose, CA and is affiliated with multiple hospitals in the area, including Community Regional Medical Center, El Camino Hospital, and Regional Medical Center of San Jose. She received her medical degree from TD Medical College Kerala and has been in practice 16 years. She specializes in hospital medicine/hospitalist.

closepopup
Pravin J. Mishra, PhD, MBADirector, Ohio State University Comprehensive Cancer Center

Pravin Mishra, has contributed significantly to innovative discoveries (basic, translational, and clinical research). His career reflects success in academic, government, not-for-profit, start-up, and healthcare settings. He is a strategic visionary executive leader, with over 15 years of experience, excelled in discovery, leadership, teaching (to trainees, pre-med, medical, Ph.D., and post-doc students), operations, recruitment/team-development, innovation, technology transfer, and strategic new business development. He developed subject expertise in oncology, stem cells, cancer genomics, drug discovery, and developmental therapeutics. He has demonstrated commitment to scientific excellence and scientific rigor as evidenced by well documented international peer-reviewed publications, awards, and presentations (>60). He has handled key executive decision making (~$80M), promoted innovation in the company to develop new business. He has established genomics (CLIA/CAP accredited) and R&D laboratories to facilitate translational research (bench-to-bedside) and to advance precision medicine efforts. He has established new business from scratch, consulted to define start-up strategies, designed and developed new and successful products.

Pravin J. Mishra, PhD, MBADirector, Ohio State University Comprehensive Cancer Center

Pravin Mishra, has contributed significantly to innovative discoveries (basic, translational, and clinical research). His career reflects success in academic, government, not-for-profit, start-up, and healthcare settings. He is a strategic visionary executive leader, with over 15 years of experience, excelled in discovery, leadership, teaching (to trainees, pre-med, medical, Ph.D., and post-doc students), operations, recruitment/team-development, innovation, technology transfer, and strategic new business development. He developed subject expertise in oncology, stem cells, cancer genomics, drug discovery, and developmental therapeutics. He has demonstrated commitment to scientific excellence and scientific rigor as evidenced by well documented international peer-reviewed publications, awards, and presentations (>60). He has handled key executive decision making (~$80M), promoted innovation in the company to develop new business. He has established genomics (CLIA/CAP accredited) and R&D laboratories to facilitate translational research (bench-to-bedside) and to advance precision medicine efforts. He has established new business from scratch, consulted to define start-up strategies, designed and developed new and successful products.

closepopup
Bassam El-Fahmawi, M.Sc., Ph.D.President CTO, Mawi DNA Technologies

Bassam El-Fahmawi is President CTO, at the Mawi DNA Technologies. He strongly believe that science is simple and need to be approached accordingly. Removing barriers to enable interdisciplinary collaborations is critical for accelerating innovation and driving new discoveries! He is open to scientific collaborations and partnerships.

Bassam El-Fahmawi, M.Sc., Ph.D.President CTO, Mawi DNA Technologies

Bassam El-Fahmawi is President CTO, at the Mawi DNA Technologies. He strongly believe that science is simple and need to be approached accordingly. Removing barriers to enable interdisciplinary collaborations is critical for accelerating innovation and driving new discoveries! He is open to scientific collaborations and partnerships.

closepopup
Anoop Ambika, MBACEO, CLAP Research & Genpro Research

Anoop P Ambika is a serial entrepreneur, organizer and a technology enthusiast. He is the co-founder of several technology/ environment startups and currently is Chief Executive Officer of CLAP Research and Genpro Research

CLAP Research brings together a team of Machine Learning, Statistics, NLP and Cognitive Neuroscience specialists to enable the transition of enterprise applications from deterministic systems to implicit learning systems.

Genpro Research is a Contract research organization with a mission to digitally disrupt the way clinical trials are conducted. Comprised of a team of very senior statisticians and research professionals from US & India, we are one of the best in the world when it comes to Bayesian analysis and Adaptive Designs.

Anoop conceptualized and co-founded, Kreara Solutions one of the first data analytics companies in India in 2004 quickly gained traction in clinical trials and predictive analytics and managed the company for 12 years. Kreara was acquired in December 2015 and later rebranded as Cognub Decision Solutions

A graduate in Computer Science and Engineering from TKM College of Engineering, University of Kerala, Anoop worked with multi-nationals like GE, NEC, Lucent and Nortel in various managerial capacities before starting Kreara. When working with GE, he was also instrumental with the ISO and Six Sigma quality initiatives that were being undertaken by the company in the late 90’s. He underwent his management education in F W Olin Graduate School of Management at Wellesley, Massachusetts. He is also a post graduate in Computational Biology & Bioinformatics from University of Kerala.

He is also a director of Verde Eco Solutions, a green initiative which ventures into decentralized ways of waste management and Katalyst, an accelerator which promotes a 100 day program to seed and germinate an idea.

Anoop Ambika, MBACEO, CLAP Research & Genpro Research

Anoop P Ambika is a serial entrepreneur, organizer and a technology enthusiast. He is the co-founder of several technology/ environment startups and currently is Chief Executive Officer of CLAP Research and Genpro Research

CLAP Research brings together a team of Machine Learning, Statistics, NLP and Cognitive Neuroscience specialists to enable the transition of enterprise applications from deterministic systems to implicit learning systems.

Genpro Research is a Contract research organization with a mission to digitally disrupt the way clinical trials are conducted. Comprised of a team of very senior statisticians and research professionals from US & India, we are one of the best in the world when it comes to Bayesian analysis and Adaptive Designs.

Anoop conceptualized and co-founded, Kreara Solutions one of the first data analytics companies in India in 2004 quickly gained traction in clinical trials and predictive analytics and managed the company for 12 years. Kreara was acquired in December 2015 and later rebranded as Cognub Decision Solutions

A graduate in Computer Science and Engineering from TKM College of Engineering, University of Kerala, Anoop worked with multi-nationals like GE, NEC, Lucent and Nortel in various managerial capacities before starting Kreara. When working with GE, he was also instrumental with the ISO and Six Sigma quality initiatives that were being undertaken by the company in the late 90’s. He underwent his management education in F W Olin Graduate School of Management at Wellesley, Massachusetts. He is also a post graduate in Computational Biology & Bioinformatics from University of Kerala.

He is also a director of Verde Eco Solutions, a green initiative which ventures into decentralized ways of waste management and Katalyst, an accelerator which promotes a 100 day program to seed and germinate an idea.

closepopup
Kristine Mechem Ph.DVP Diagnostics at Health Advances

Kristine has over 15 years of Life Science industry experience that spans diagnostics, medical devices, and therapeutics. She has held positions in market planning, business analytics, marketing, and business development.

Most recently, Kristine spent four years at a small cap oncology molecular diagnostic company where she led marketing and planning. During that time, she helped to take the company public, led the portfolio management and corporate planning efforts, and developed the commercial plan for their launch. She led the team that was responsible for the full range of commercial activities including: product development requirements, pricing strategy, market access strategy, salesforce sizing and customer service.

In addition to her oncology experience, Kristine has worked in metabolics, with positions at Genentech and Abbott, and in maternal health (early stage molecular diagnostic company). During her career she has been on five product launch teams with responsibilities for launch planning and KPI tracking.

Prior to her Life Science career, Kristine spent 15 years in commercial positions in high tech.

Kristine has a PhD from the University of Chicago and has completed the Executive Program in Strategy and Organization from the Stanford Graduate School of Business. She is also an active member of Women in Bio.

Kristine Mechem Ph.DVP Diagnostics at Health Advances

Kristine has over 15 years of Life Science industry experience that spans diagnostics, medical devices, and therapeutics. She has held positions in market planning, business analytics, marketing, and business development.

Most recently, Kristine spent four years at a small cap oncology molecular diagnostic company where she led marketing and planning. During that time, she helped to take the company public, led the portfolio management and corporate planning efforts, and developed the commercial plan for their launch. She led the team that was responsible for the full range of commercial activities including: product development requirements, pricing strategy, market access strategy, salesforce sizing and customer service.

In addition to her oncology experience, Kristine has worked in metabolics, with positions at Genentech and Abbott, and in maternal health (early stage molecular diagnostic company). During her career she has been on five product launch teams with responsibilities for launch planning and KPI tracking.

Prior to her Life Science career, Kristine spent 15 years in commercial positions in high tech.

Kristine has a PhD from the University of Chicago and has completed the Executive Program in Strategy and Organization from the Stanford Graduate School of Business. She is also an active member of Women in Bio.

closepopup
Panna SharmaCEO, Lantern Pharma

Panna Sharma is the President, CEO, and Board member of Lantern Pharma, a clinical-stage oncology biotech using artificial intelligence (AI) and genomics to innovate the rescue, revitalization, and development of precision cancer therapeutics. Lantern is focused on improving patient outcomes by using its proprietary AI platform – Response Algorithm for Drug Repositioning & Rescue (RADR™) – to rescue, revitalize and develop abandoned or failed cancer drugs, and to accelerate their development through precision trials that help identify patient groups more likely to respond to its pipeline of targeted cancer therapies.

As Chief Executive Officer, Panna is responsible for developing Lantern’s strategic vision, and working closely with the venture investors to raise capital that will place the Company at the forefront of using AI and genomics in developing its pipeline of precision therapies. The Lantern Pharma (LP) pipeline currently includes three drugs – two in clinical stages and one in preclinical, all focusing on cancers that have unique and unmet clinical needs with a clearly defined patient population. These drugs can be targeted to patients whose profile identifies them as having the highest probability of benefiting from the drug, thereby achieving better outcomes with reduced costs and accelerated timelines.

Prior to joining Lantern in 2018, Panna was the President and Chief Executive Officer of Cancer Genetics, Inc. (Nasdaq: CGIX), a provider of genomic and immune-based cancer diagnostics and therapy development services to some of the most prestigious medical institutions and pharma companies in the world. In his capacity as CEO at CGIX, he raised over $100 million in the public and private markets and grew the company from 25 employees in New Jersey to over 250 employees globally across multiple continents. Panna took CGIX public in 2013 and acquired four companies globally that help CGIX deliver on its mission to help personalize cancer treatment. Prior to CGIX, Panna founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create shareholder value for companies and investors in the life sciences, biotechnology, and environmental sciences. Panna began his career as an industry analyst for financial services and technology companies and was part of the management team that took the digital strategy and e-business company iXL public.

Panna attended Boston University in the University Professors Program and focused his studies on Philosophy of Science, Neural Networks and Artificial Intelligence. When not focused on the future of biotech, machine learning, emerging technologies, and genomics, Panna can be found with his three children and wife and listening to music, attending sports functions, discussing new and ethical uses of AI, and enjoying the vibrant food scene in Atlanta.

Panna SharmaCEO, Lantern Pharma

Panna Sharma is the President, CEO, and Board member of Lantern Pharma, a clinical-stage oncology biotech using artificial intelligence (AI) and genomics to innovate the rescue, revitalization, and development of precision cancer therapeutics. Lantern is focused on improving patient outcomes by using its proprietary AI platform – Response Algorithm for Drug Repositioning & Rescue (RADR™) – to rescue, revitalize and develop abandoned or failed cancer drugs, and to accelerate their development through precision trials that help identify patient groups more likely to respond to its pipeline of targeted cancer therapies.

As Chief Executive Officer, Panna is responsible for developing Lantern’s strategic vision, and working closely with the venture investors to raise capital that will place the Company at the forefront of using AI and genomics in developing its pipeline of precision therapies. The Lantern Pharma (LP) pipeline currently includes three drugs – two in clinical stages and one in preclinical, all focusing on cancers that have unique and unmet clinical needs with a clearly defined patient population. These drugs can be targeted to patients whose profile identifies them as having the highest probability of benefiting from the drug, thereby achieving better outcomes with reduced costs and accelerated timelines.

Prior to joining Lantern in 2018, Panna was the President and Chief Executive Officer of Cancer Genetics, Inc. (Nasdaq: CGIX), a provider of genomic and immune-based cancer diagnostics and therapy development services to some of the most prestigious medical institutions and pharma companies in the world. In his capacity as CEO at CGIX, he raised over $100 million in the public and private markets and grew the company from 25 employees in New Jersey to over 250 employees globally across multiple continents. Panna took CGIX public in 2013 and acquired four companies globally that help CGIX deliver on its mission to help personalize cancer treatment. Prior to CGIX, Panna founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create shareholder value for companies and investors in the life sciences, biotechnology, and environmental sciences. Panna began his career as an industry analyst for financial services and technology companies and was part of the management team that took the digital strategy and e-business company iXL public.

Panna attended Boston University in the University Professors Program and focused his studies on Philosophy of Science, Neural Networks and Artificial Intelligence. When not focused on the future of biotech, machine learning, emerging technologies, and genomics, Panna can be found with his three children and wife and listening to music, attending sports functions, discussing new and ethical uses of AI, and enjoying the vibrant food scene in Atlanta.

closepopup
Arijit BhattacharyyaFounder, and CEO, Virtualinfocom

An entrepreneur since 1998, Arijit Bhattacharyya is founder of Virtualinfocom. Founder- animgaming, cosplayseller, Co-Founder-Sportszonein MD-virtualgamedeveloper, Founder Entrepreneursface.

He is the creator of India's one of the first 3D games based on mythology and culture.
R & D partner & creator of of Virtual Reality solution since 2001. He is creator of India’s one of the first Virtual Reality institute & lab.
His expertise lies in the areas of International Business Development, Business Strategy, New Market Development, Risk Management, Market Entry, New Technology, Deeptech, Systems & Processes and Fund-raising.
For the last several years Arijit is speaking in various national and international platform about Intellectual Property, Innovation, Cyber Security, game development, virtual reality, scale up business, wealth management, startup ecosystem and IP. Example: NEN, TiE, CII, China VR Film Festival, Game Show(Korea), Passion for game (Singapore), IIT EDC, IIM Innovation Lab, Digimation-UK etc.

Arijit BhattacharyyaFounder, and CEO, Virtualinfocom

An entrepreneur since 1998, Arijit Bhattacharyya is founder of Virtualinfocom. Founder- animgaming, cosplayseller, Co-Founder-Sportszonein MD-virtualgamedeveloper, Founder Entrepreneursface.

He is the creator of India's one of the first 3D games based on mythology and culture.
R & D partner & creator of of Virtual Reality solution since 2001. He is creator of India’s one of the first Virtual Reality institute & lab.
His expertise lies in the areas of International Business Development, Business Strategy, New Market Development, Risk Management, Market Entry, New Technology, Deeptech, Systems & Processes and Fund-raising.
For the last several years Arijit is speaking in various national and international platform about Intellectual Property, Innovation, Cyber Security, game development, virtual reality, scale up business, wealth management, startup ecosystem and IP. Example: NEN, TiE, CII, China VR Film Festival, Game Show(Korea), Passion for game (Singapore), IIT EDC, IIM Innovation Lab, Digimation-UK etc.

closepopup
Krish Chakrabarti, MBAHead Risk and BD, Medical iSight

Krish Chakrabarti is an experienced capital markets and health care professional with track record in business development . Extensive knowledge of financial markets , trading and risk management with broad coverage of financial products . Recent focus in healthcare technology sector in developing SaaS for AI - enabled and image-guided 3D surgery . Steering innovation and strategic developments to deliver better outcomes and ROI in digital surgery. Education background includes MBA in Finance and Bachelor of Science (BSc) in Mathematical Physics.
Strong client connections at a global scale.

Krish Chakrabarti, MBAHead Risk and BD, Medical iSight

Krish Chakrabarti is an experienced capital markets and health care professional with track record in business development . Extensive knowledge of financial markets , trading and risk management with broad coverage of financial products . Recent focus in healthcare technology sector in developing SaaS for AI - enabled and image-guided 3D surgery . Steering innovation and strategic developments to deliver better outcomes and ROI in digital surgery. Education background includes MBA in Finance and Bachelor of Science (BSc) in Mathematical Physics.
Strong client connections at a global scale.

closepopup
Steven A. Bogen, MD, Ph.D.CEO, Boston Cell Standards, Medical Director, Clinical Chemistry Laboratory, Tufts Medical Center

Dr. Bogen is CEO of Boston Cell Standards and Medical Director, Clinical Chemistry Laboratory, Tufts Medical Center, Boston MA. Over the last 20 years, he has been an NIH-funded investigator developing a better understanding of, and better technologies for, in situ protein detection and quantification. During the last 5 years, he and his colleagues developed new methods and technologies for applying the standardization principles of measurement traceability found in clinical chemistry to immunohistochemistry testing.

Steven A. Bogen, MD, Ph.D.CEO, Boston Cell Standards, Medical Director, Clinical Chemistry Laboratory, Tufts Medical Center

Dr. Bogen is CEO of Boston Cell Standards and Medical Director, Clinical Chemistry Laboratory, Tufts Medical Center, Boston MA. Over the last 20 years, he has been an NIH-funded investigator developing a better understanding of, and better technologies for, in situ protein detection and quantification. During the last 5 years, he and his colleagues developed new methods and technologies for applying the standardization principles of measurement traceability found in clinical chemistry to immunohistochemistry testing.

closepopup
Pratip K. Chattopadhyay, PhDAssociate Professor and founding Director of NYU Langone Health’s Precision Immunology Laboratory

Pratip Chattopadhyay is an Associate Professor and founding Director of NYU Langone Health’s Precision Immunology Laboratory (PIL). His laboratory performs research in tumor immunology and provides cutting-edge immune monitoring services for a wide variety of biomedical disciplines (cancer, infectious disease, autoimmunity). He uses high parameter cytometry technologies, including 30-parameter flow cytometry and combined protein/mRNA analysis by RNA sequencing (molecular cytometry), to reveal biomarkers that predict patient outcomes, better understand disease pathogenesis, and inform rational design of combination drug therapies.

Dr. Chattopadhyay has a history of innovative work in the cytometry and immunoassay space. In 2005, as a post-doctoral fellow in Mario Roederer’s laboratory (VRC/NIH), he developed a novel assay for enumeration and isolation of antigen-specific CD4+ T-cells, based on CD154 expression (Chattopadhyay, et al. Nature Medicine, 2005). In 2006, he reported the first 18-color flow cytometry experiments, which were used to comprehensively characterize antigen-specific T-cells against multiple antigenic epitopes in the same tube (Chattopadhyay, et al. Nature Medicine 2006); this study was the first use of quantum dots for flow cytometry. In 2008, he performed the first flow cytometry experiments with the Brilliant family of fluorescent dyes, which were published in 2010. This work increased the multiplexing capability of advanced flow cytometers, culminating in the development of the most advanced flow cytometry system in the world (30-parameter flow cytometry). Dr. Chattopadhyay co-led this effort for the Roederer Lab with BD Biosciences. He also led the first CyTOF program at the NIH, and contributed to the development of CITE-seq (benchmarking the new technology against flow cytometry, Nature Methods 2017). Finally, Dr. Chattopadhyay played a key role in the development of a number of bioinformatics tools for analyzing high parameter data, including SPICE (Roederer), flowType and R-chyoptimyx (Aghaheepour and Brinkman), and CytoBrute (new from the Chattopadhyay lab). Recently, the lab introduced a unique tool for building high parameter flow cytometry panels, known as Color Wheel.

Dr. Chattopadhyay serves as an Associate Editor for the journal Cytometry and a Review Editor for Frontiers in Immunology. He was a council member for the International Society for the Advancement of Cytometry (ISAC), and was Scientific Chair for CYTO2019, and planned and emceed CYTO Virtual 2020. He is a proud graduate of the Johns Hopkins Bloomberg School of Public Health (Ph.D.) and the University of Virginia (B.A.). He lives in Mendham, New Jersey with his wife, daughter, and three dogs, where he is active in the local community as founder of Sci! (a scientific mentorship program for disadvantaged youth) and Mendham Blue (a social/political group that advocates for the public interest in local and regional government).

Pratip K. Chattopadhyay, PhDAssociate Professor and founding Director of NYU Langone Health’s Precision Immunology Laboratory

Pratip Chattopadhyay is an Associate Professor and founding Director of NYU Langone Health’s Precision Immunology Laboratory (PIL). His laboratory performs research in tumor immunology and provides cutting-edge immune monitoring services for a wide variety of biomedical disciplines (cancer, infectious disease, autoimmunity). He uses high parameter cytometry technologies, including 30-parameter flow cytometry and combined protein/mRNA analysis by RNA sequencing (molecular cytometry), to reveal biomarkers that predict patient outcomes, better understand disease pathogenesis, and inform rational design of combination drug therapies.

Dr. Chattopadhyay has a history of innovative work in the cytometry and immunoassay space. In 2005, as a post-doctoral fellow in Mario Roederer’s laboratory (VRC/NIH), he developed a novel assay for enumeration and isolation of antigen-specific CD4+ T-cells, based on CD154 expression (Chattopadhyay, et al. Nature Medicine, 2005). In 2006, he reported the first 18-color flow cytometry experiments, which were used to comprehensively characterize antigen-specific T-cells against multiple antigenic epitopes in the same tube (Chattopadhyay, et al. Nature Medicine 2006); this study was the first use of quantum dots for flow cytometry. In 2008, he performed the first flow cytometry experiments with the Brilliant family of fluorescent dyes, which were published in 2010. This work increased the multiplexing capability of advanced flow cytometers, culminating in the development of the most advanced flow cytometry system in the world (30-parameter flow cytometry). Dr. Chattopadhyay co-led this effort for the Roederer Lab with BD Biosciences. He also led the first CyTOF program at the NIH, and contributed to the development of CITE-seq (benchmarking the new technology against flow cytometry, Nature Methods 2017). Finally, Dr. Chattopadhyay played a key role in the development of a number of bioinformatics tools for analyzing high parameter data, including SPICE (Roederer), flowType and R-chyoptimyx (Aghaheepour and Brinkman), and CytoBrute (new from the Chattopadhyay lab). Recently, the lab introduced a unique tool for building high parameter flow cytometry panels, known as Color Wheel.

Dr. Chattopadhyay serves as an Associate Editor for the journal Cytometry and a Review Editor for Frontiers in Immunology. He was a council member for the International Society for the Advancement of Cytometry (ISAC), and was Scientific Chair for CYTO2019, and planned and emceed CYTO Virtual 2020. He is a proud graduate of the Johns Hopkins Bloomberg School of Public Health (Ph.D.) and the University of Virginia (B.A.). He lives in Mendham, New Jersey with his wife, daughter, and three dogs, where he is active in the local community as founder of Sci! (a scientific mentorship program for disadvantaged youth) and Mendham Blue (a social/political group that advocates for the public interest in local and regional government).

closepopup
Brisa Fernandes, MD, Ph.D.The University of Texas Health Science Center

My main research field focuses on the discovery and application of biomarkers in bipolar disorder, major depressive disorder, and schizophrenia. I started in this field in 2008 during my psychiatric training and in 2009 published what is perhaps the first proposal of employment of blood biomarkers as an adjunctive tool for the differential diagnosis of bipolar and unipolar depression. My masters degree investigated and proposed the protein brain-derived neurotrophic factor (BDNF) as a biomarker of disease activity in bipolar disorder. It was awarded the Samuel Gershon Award for Junior Investigators by The International Society for Bipolar Disorders in 2010, and the article published is on the top 1% most cited papers in Psychiatry and Psychology according to Web of Science Indicators. I enroled for a doctorate in Biochemistry at the Federal University of Rio Grande do Sul (UFRGS), one of the leading universities in Brazil. My Ph.D. thesis analysed the role of BDNF as a biomarker across the schizoaffective spectrum and establish that BDNF as a potential biomarker of disease activity for the acute phases of bipolar disorder and major depressive disorder. Presently, I am a post-doctoral research fellow in Australia at Deakin University, School of Medicine, under the supervision of Prof. Michael Berk, a well-known expert in bipolar disorder. I am an active researcher, with more than 25 articles in peer-reviewed journals, an H-index of 15 and more than 1,100 citations (Google Scholar, December 2015). Currently, I hold a research grant from CNPq, Brazil. I graduated in Medicine in 2002 and specialised in Internal Medicine and Psychiatry in 2005 and 2009, respectively. During my graduation years, I acquired extensive experience in Epidemiology, and my residency training in Internal Medicine provided me a deep understanding of clinical tests. My diverse but complementary skills provide with a unique view for the discovery and validation of biomarkers in psychiatry.

Brisa Fernandes, MD, Ph.D.The University of Texas Health Science Center

My main research field focuses on the discovery and application of biomarkers in bipolar disorder, major depressive disorder, and schizophrenia. I started in this field in 2008 during my psychiatric training and in 2009 published what is perhaps the first proposal of employment of blood biomarkers as an adjunctive tool for the differential diagnosis of bipolar and unipolar depression. My masters degree investigated and proposed the protein brain-derived neurotrophic factor (BDNF) as a biomarker of disease activity in bipolar disorder. It was awarded the Samuel Gershon Award for Junior Investigators by The International Society for Bipolar Disorders in 2010, and the article published is on the top 1% most cited papers in Psychiatry and Psychology according to Web of Science Indicators. I enroled for a doctorate in Biochemistry at the Federal University of Rio Grande do Sul (UFRGS), one of the leading universities in Brazil. My Ph.D. thesis analysed the role of BDNF as a biomarker across the schizoaffective spectrum and establish that BDNF as a potential biomarker of disease activity for the acute phases of bipolar disorder and major depressive disorder. Presently, I am a post-doctoral research fellow in Australia at Deakin University, School of Medicine, under the supervision of Prof. Michael Berk, a well-known expert in bipolar disorder. I am an active researcher, with more than 25 articles in peer-reviewed journals, an H-index of 15 and more than 1,100 citations (Google Scholar, December 2015). Currently, I hold a research grant from CNPq, Brazil. I graduated in Medicine in 2002 and specialised in Internal Medicine and Psychiatry in 2005 and 2009, respectively. During my graduation years, I acquired extensive experience in Epidemiology, and my residency training in Internal Medicine provided me a deep understanding of clinical tests. My diverse but complementary skills provide with a unique view for the discovery and validation of biomarkers in psychiatry.

closepopup
Asad Zaidi, MBACEO, Epinex Diagnostics and RedApple Digital Health

Asad R. Zaidi, President & CEO is a biochemist and biomedical engineer graduated with honors from University of California, Irvine. He has been involved with the development of heart valves, artificial coronary arteries, membrane oxygenators, dialyzers and various in-vitro-diagnostic and biomedical devices since 1973. His experience of over 25 years spans the growth of biomedical devices in companies such as Shiley (Pfizer), C.R. Bard, Mitral Medical, Bicer Medical, and Medtronic. He has been responsible for licensing and transferring medical device manufacturing technology from Latin America to Canada and to England. His areas of expertise range from product development to patenting and production. He has written and assisted in FDA submissions of 510k pre-market notifications, investigational device exemptions (IDE), and pre-market authorizations (PMA).

Asad Zaidi, MBACEO, Epinex Diagnostics and RedApple Digital Health

Asad R. Zaidi, President & CEO is a biochemist and biomedical engineer graduated with honors from University of California, Irvine. He has been involved with the development of heart valves, artificial coronary arteries, membrane oxygenators, dialyzers and various in-vitro-diagnostic and biomedical devices since 1973. His experience of over 25 years spans the growth of biomedical devices in companies such as Shiley (Pfizer), C.R. Bard, Mitral Medical, Bicer Medical, and Medtronic. He has been responsible for licensing and transferring medical device manufacturing technology from Latin America to Canada and to England. His areas of expertise range from product development to patenting and production. He has written and assisted in FDA submissions of 510k pre-market notifications, investigational device exemptions (IDE), and pre-market authorizations (PMA).

closepopup
Yan LeyfmanDirector of Immunology Division, WACEM-ACAIM COVID-19 Taskforce

Yan Leyfman is a medical student at Memorial Sloan Kettering Cancer Center. His work has been recognized by the American Society of Hematology, American Society of Clinical Oncology, and the International Society of Immunology & Immunochemistry (iChem). Several weeks ago, he was recognized as the 2020 Emerging International Scholar in Immunology & Immunotherapy by iChem. Mr. Leyfman has contributed to the development of several anti-cancer therapies that have recently entered clinical trials and his successes have been recognized by such prestigious organizations as the Barry M. Goldwater Research Foundation, Sigma Xi, New York Times, USA Today, National Society of Collegiate Scholars, and Harvard Medical School. During the COVID-19 pandemic, he was recruited to join the Global COVID-19 Taskforce to serve as a Special Advisor for Immunology, Oncology and Cellular Therapeutics and was made Director of the Immunology Group, which produced a cohesive mechanism of action for SARS-CoV-2, a new prognostic assay to predict patient outcomes, and the first synergistic paradigm between the flu and SARS-CoV-2, termed "COVI-Flu" along with therapeutic interventions for both. Yan was recognized as a 2020 New York State & City Manhattan Hero for his community service and research contributions during the COVID-19 pandemic and by Memorial Sloan Kettering Cancer Center for research excellence.

Yan LeyfmanDirector of Immunology Division, WACEM-ACAIM COVID-19 Taskforce

Yan Leyfman is a medical student at Memorial Sloan Kettering Cancer Center. His work has been recognized by the American Society of Hematology, American Society of Clinical Oncology, and the International Society of Immunology & Immunochemistry (iChem). Several weeks ago, he was recognized as the 2020 Emerging International Scholar in Immunology & Immunotherapy by iChem. Mr. Leyfman has contributed to the development of several anti-cancer therapies that have recently entered clinical trials and his successes have been recognized by such prestigious organizations as the Barry M. Goldwater Research Foundation, Sigma Xi, New York Times, USA Today, National Society of Collegiate Scholars, and Harvard Medical School. During the COVID-19 pandemic, he was recruited to join the Global COVID-19 Taskforce to serve as a Special Advisor for Immunology, Oncology and Cellular Therapeutics and was made Director of the Immunology Group, which produced a cohesive mechanism of action for SARS-CoV-2, a new prognostic assay to predict patient outcomes, and the first synergistic paradigm between the flu and SARS-CoV-2, termed "COVI-Flu" along with therapeutic interventions for both. Yan was recognized as a 2020 New York State & City Manhattan Hero for his community service and research contributions during the COVID-19 pandemic and by Memorial Sloan Kettering Cancer Center for research excellence.

closepopup
Jimmy QianCo-founder and COO, Osmind, Stanford University

Jimmy Qian is the co-founder and COO of Osmind, a precision mental health company backed by General Catalyst and Y Combinator. He is also an MD candidate and researcher at Stanford University School of Medicine. He previously co-founded/led 3 nonprofits (all still active and successful) spanning community healthcare for underserved populations, immersive technologies for pediatric healthcare, and a STEM research institute.

Jimmy QianCo-founder and COO, Osmind, Stanford University

Jimmy Qian is the co-founder and COO of Osmind, a precision mental health company backed by General Catalyst and Y Combinator. He is also an MD candidate and researcher at Stanford University School of Medicine. He previously co-founded/led 3 nonprofits (all still active and successful) spanning community healthcare for underserved populations, immersive technologies for pediatric healthcare, and a STEM research institute.

closepopup
Amreen Khan, MTechScientist, Indian Institute of Technology

Technology Enthusiast, always looking to learn something new. I have a very large appetite of learning. I love to solve complex problems and loves to deep dive in them for finding the best solution. I am very passionate about my work and believe myself to be very result oriented.

Qualified with a demonstrated history of working in innovation led biotechnology industry. Skilled in Recombinant DNA, Pharmaceutical Research, Biotechnology, Molecular & Cellular Biology, biomaterials and Nanotechnology. Strong professional with a Master’s Degree focused on Pharmaceutical Biotechnology from National Institute of Pharmaceutical Education and Research (NIPER), SAS NAGAR, Mohali.

Amreen Khan, MTechScientist, Indian Institute of Technology

Technology Enthusiast, always looking to learn something new. I have a very large appetite of learning. I love to solve complex problems and loves to deep dive in them for finding the best solution. I am very passionate about my work and believe myself to be very result oriented.

Qualified with a demonstrated history of working in innovation led biotechnology industry. Skilled in Recombinant DNA, Pharmaceutical Research, Biotechnology, Molecular & Cellular Biology, biomaterials and Nanotechnology. Strong professional with a Master’s Degree focused on Pharmaceutical Biotechnology from National Institute of Pharmaceutical Education and Research (NIPER), SAS NAGAR, Mohali.

closepopup

AAPM Annual Meeting Past Speakers

Shweta Singh ManiarGlobal Healthcare & Life Sciences Leader, Google

At Google Cloud, Shweta is the strategic client lead responsible for Healthcare and Life Sciences. Shweta has quickly risen through the ranks as a well-known innovator, game-changer, and relationship ambassador. With 18+ years’ experience in clinical research, Healthcare and Bio Tech, she has proven time and time again how valuable relationships can be by enabling dozens of start-up firms with access to capital from Federal grants and VC firms alike. She brings an eye for detail, winning contract negotiations, and financial insight to support her commercial partnership strategy expertise. A position was created just for her, after excelling in a Commercial Partnering and Strategy role at Genentech. She has been the recipient of multiple awards at Genentech, including two “Innovation Awards,” “MVP Award,” and more. Shweta brings an impressive network of established healthcare system relationships across Digital Health & Technology, Investor, Pharmaceutical, Medical Device, and Hospital Systems Industries. She is passionate about keeping current with trends in medical devices, data, wearables, IoT, EHR, and machine learning. Since joining Google, Shweta develops and manages a variety of customer and partnership relationships while identifying new opportunities.

Shweta Singh ManiarGlobal Healthcare & Life Sciences Leader, Google

At Google Cloud, Shweta is the strategic client lead responsible for Healthcare and Life Sciences. Shweta has quickly risen through the ranks as a well-known innovator, game-changer, and relationship ambassador. With 18+ years’ experience in clinical research, Healthcare and Bio Tech, she has proven time and time again how valuable relationships can be by enabling dozens of start-up firms with access to capital from Federal grants and VC firms alike. She brings an eye for detail, winning contract negotiations, and financial insight to support her commercial partnership strategy expertise. A position was created just for her, after excelling in a Commercial Partnering and Strategy role at Genentech. She has been the recipient of multiple awards at Genentech, including two “Innovation Awards,” “MVP Award,” and more. Shweta brings an impressive network of established healthcare system relationships across Digital Health & Technology, Investor, Pharmaceutical, Medical Device, and Hospital Systems Industries. She is passionate about keeping current with trends in medical devices, data, wearables, IoT, EHR, and machine learning. Since joining Google, Shweta develops and manages a variety of customer and partnership relationships while identifying new opportunities.

closepopup
Sangeeta Marwaha, MDChair, Dermatology Technology Leads, Kaiser Permanente

Sangeeta Marwaha, MD is Chair of the Dermatology Technology Leads at Kaiser Permanente. She is a Medical and Surgical Dermatologist who is also a part of regional dermatology leadership team at Kaiser.
She is the Chief of Cosmetic Dermatology at Kaiser Permanente and an Clinical Instructor, UC Davis Dermatology Residency Program. She is also a part of Physician Wellness Program and Epic Dermatology Steering Committee.

Sangeeta Marwaha, MDChair, Dermatology Technology Leads, Kaiser Permanente

Sangeeta Marwaha, MD is Chair of the Dermatology Technology Leads at Kaiser Permanente. She is a Medical and Surgical Dermatologist who is also a part of regional dermatology leadership team at Kaiser.
She is the Chief of Cosmetic Dermatology at Kaiser Permanente and an Clinical Instructor, UC Davis Dermatology Residency Program. She is also a part of Physician Wellness Program and Epic Dermatology Steering Committee.

closepopup
Pier Federico Gherardini, PhDDirector, Informatics, Parker Institute for Cancer Immunotherapy

Pier Federico Gherardini, PhD, is director of informatics at PICI. His work focuses on the development of computational methods for the visualization and analysis of high-dimensional data, with a particular focus on single-cell analysis.

Gherardini has a strong passion for the development and application of new technologies and for thinking about the challenges such technologies bring to data analysis and interpretation. At PICI, his work focuses on the implementation of advanced assay technologies for the analysis of clinical samples, from evaluating new approaches to developing computational methods to visualize and analyze the resulting data. Gherardini is also interested in tools that support human-driven analysis of complex datasets, including interactive visualization methods and information systems that can support a rapid iteration cycle of analysis and interpretation.

Prior to joining PICI, Gherardini was a postdoctoral fellow in the lab of Garry P. Nolan, PhD, at Stanford, where he performed both computational and wet lab work. While at Stanford he developed a technology for highly multiplexed simultaneous measurement of proteins and RNAs in single cells by mass cytometry, as well as a method for building an interactive map of the immune system that incorporates prior knowledge about major cell types.

Gherardini holds master’s and doctoral degrees from the University of Rome Tor Vergata in Italy and a certificate from the Ignite program in innovation and entrepreneurship from the Stanford University Graduate School of Business.

Pier Federico Gherardini, PhDDirector, Informatics, Parker Institute for Cancer Immunotherapy

Pier Federico Gherardini, PhD, is director of informatics at PICI. His work focuses on the development of computational methods for the visualization and analysis of high-dimensional data, with a particular focus on single-cell analysis.

Gherardini has a strong passion for the development and application of new technologies and for thinking about the challenges such technologies bring to data analysis and interpretation. At PICI, his work focuses on the implementation of advanced assay technologies for the analysis of clinical samples, from evaluating new approaches to developing computational methods to visualize and analyze the resulting data. Gherardini is also interested in tools that support human-driven analysis of complex datasets, including interactive visualization methods and information systems that can support a rapid iteration cycle of analysis and interpretation.

Prior to joining PICI, Gherardini was a postdoctoral fellow in the lab of Garry P. Nolan, PhD, at Stanford, where he performed both computational and wet lab work. While at Stanford he developed a technology for highly multiplexed simultaneous measurement of proteins and RNAs in single cells by mass cytometry, as well as a method for building an interactive map of the immune system that incorporates prior knowledge about major cell types.

Gherardini holds master’s and doctoral degrees from the University of Rome Tor Vergata in Italy and a certificate from the Ignite program in innovation and entrepreneurship from the Stanford University Graduate School of Business.

closepopup
Robin FarmanfarmaianAuthor, Patient Advocate, Entrepreneur

Robin Farmanfarmaian is a professional speaker, entrepreneur, and angel investor working with cutting-edge Artificial Intelligence software, device and pharma companies poised to impact 100M patients.

With over 140 speaking engagements in 13 countries, she educates audiences on the future of healthcare, patient empowerment, building thought leadership, and many trends & technologies: Artificial intelligence, sensors, tissue engineering, nano, 3D printing, virtual healthcare, point of care diagnostics + medical device and more.

Robin has 2 published books: “The Patient as CEO: How Technology Empowers the Healthcare Consumer” and "The Thought Leader Formula: Strategically Leverage Your Expertise to Drive Business & Career Goals".

Robin FarmanfarmaianAuthor, Patient Advocate, Entrepreneur

Robin Farmanfarmaian is a professional speaker, entrepreneur, and angel investor working with cutting-edge Artificial Intelligence software, device and pharma companies poised to impact 100M patients.

With over 140 speaking engagements in 13 countries, she educates audiences on the future of healthcare, patient empowerment, building thought leadership, and many trends & technologies: Artificial intelligence, sensors, tissue engineering, nano, 3D printing, virtual healthcare, point of care diagnostics + medical device and more.

Robin has 2 published books: “The Patient as CEO: How Technology Empowers the Healthcare Consumer” and "The Thought Leader Formula: Strategically Leverage Your Expertise to Drive Business & Career Goals".

closepopup
Nishit Doshi, PhDDirector, Roche Molecular Systems

Nishit Doshi, PhD is a director at Roche Molecular Systems. He is an influential and innovative product leader who builds high-performance teams and heads product development strategy through delivery. He is known for motivating resources and aligning vision towards performance excellence. He has implemented processes that reaches beyond the traditional organizational structure to setup teams for success. He solves complex technical challenges through innovation and translates data into insights and actionable ideas for digital health and life sciences products, from concept through commercialization. He has experience in both startups and multi-national Fortune 500 healthcare firms from the technology and business perspective.

Nishit Doshi, PhDDirector, Roche Molecular Systems

Nishit Doshi, PhD is a director at Roche Molecular Systems. He is an influential and innovative product leader who builds high-performance teams and heads product development strategy through delivery. He is known for motivating resources and aligning vision towards performance excellence. He has implemented processes that reaches beyond the traditional organizational structure to setup teams for success. He solves complex technical challenges through innovation and translates data into insights and actionable ideas for digital health and life sciences products, from concept through commercialization. He has experience in both startups and multi-national Fortune 500 healthcare firms from the technology and business perspective.

closepopup
Elizabeth Baca, MD, MPASpecialist Leader at Deloitte, Former Deputy Director, Governor's Office of Planning and Research

Elizabeth Baca, MD is a specialist leader at Deloitte. She has served as the deputy director of the Governor's Office of Planning and Research (OPR), where she provided vision, leadership and oversight for the California Initiative to Advance Precision Medicine (CIAPM). Previously, Dr. Baca served on the General Pediatric Faculty at Stanford Medical School and directed the Community Pediatric and Child Advocacy Rotation. In addition to teaching medical students and residents about the social, economic, and environmental factors that affect health, Dr. Baca was the lead faculty mentor on several projects to increase access to healthy foods, reduce environmental triggers of asthma, increase physical activity opportunities, and improve the built environment.

Dr. Baca studied health policy at Universidad Simon Bolivar in Venezuela. She completed her Masters in Public Administration at Harvard Kennedy School of Government and her medical degree at Harvard Medical School. Dr. Baca completed her pediatric residency in the Pediatric Leadership for the Underserved (PLUS) program at UC San Francisco.

Elizabeth Baca, MD, MPASpecialist Leader at Deloitte, Former Deputy Director, Governor's Office of Planning and Research

Elizabeth Baca, MD is a specialist leader at Deloitte. She has served as the deputy director of the Governor's Office of Planning and Research (OPR), where she provided vision, leadership and oversight for the California Initiative to Advance Precision Medicine (CIAPM). Previously, Dr. Baca served on the General Pediatric Faculty at Stanford Medical School and directed the Community Pediatric and Child Advocacy Rotation. In addition to teaching medical students and residents about the social, economic, and environmental factors that affect health, Dr. Baca was the lead faculty mentor on several projects to increase access to healthy foods, reduce environmental triggers of asthma, increase physical activity opportunities, and improve the built environment.

Dr. Baca studied health policy at Universidad Simon Bolivar in Venezuela. She completed her Masters in Public Administration at Harvard Kennedy School of Government and her medical degree at Harvard Medical School. Dr. Baca completed her pediatric residency in the Pediatric Leadership for the Underserved (PLUS) program at UC San Francisco.

closepopup
Kimon Angelides, PhD, MBAFounder and CEO, Vivante Health

Kim is the founder of four healthcare companies: Vivante, Livongo, the leading digital diabetes company, DiabetesAmerica, a network of diabetes centers that pioneered the at-risk and bundled payment models, and mAbGen, a cancer biotech company that partnered with MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

Kim’s newest company, Vivante Health, was created in early 2016, after he left Livongo, to tackle the needs of people who have invisible and stigmatized diseases, who have been neglected in the healthcare system. The first product, GIThrive, takes on digestive diseases which affects more than 70M Americans. Digestive trouble is something most people don’t want to discuss. It’s understandable—symptoms like diarrhea, constipation, gas and bloating are embarrassing and stigmatized and drastically impact people’s home and work lives. His goal is to destigmatize these conditions by using state of the art psychosocial, clinical, nutritional and microbiome science to improve the lives of these people and to reduce healthcare costs.

Prior to his healthcare career, Kim was the Chief Strategic Officer at Tanox, Inc which sold to Genentech (NYSE: DNA) for $1B, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kim has served on the National Medical Advisory Boards of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kim was Research Career Development Award from the NIH, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 40 patents. He received a PhD in Chemistry from the University of California and has done graduate study in business, laws, and public health.

Kimon Angelides, PhD, MBAFounder and CEO, Vivante Health

Kim is the founder of four healthcare companies: Vivante, Livongo, the leading digital diabetes company, DiabetesAmerica, a network of diabetes centers that pioneered the at-risk and bundled payment models, and mAbGen, a cancer biotech company that partnered with MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

Kim’s newest company, Vivante Health, was created in early 2016, after he left Livongo, to tackle the needs of people who have invisible and stigmatized diseases, who have been neglected in the healthcare system. The first product, GIThrive, takes on digestive diseases which affects more than 70M Americans. Digestive trouble is something most people don’t want to discuss. It’s understandable—symptoms like diarrhea, constipation, gas and bloating are embarrassing and stigmatized and drastically impact people’s home and work lives. His goal is to destigmatize these conditions by using state of the art psychosocial, clinical, nutritional and microbiome science to improve the lives of these people and to reduce healthcare costs.

Prior to his healthcare career, Kim was the Chief Strategic Officer at Tanox, Inc which sold to Genentech (NYSE: DNA) for $1B, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kim has served on the National Medical Advisory Boards of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kim was Research Career Development Award from the NIH, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 40 patents. He received a PhD in Chemistry from the University of California and has done graduate study in business, laws, and public health.

closepopup
Julianne McCall, PhDScience Officer, CIAPM, The California Governor’s Office of Planning & Research

Julianne McCall holds a PhD in Neuroscience with sixteen years of laboratory experience, including at the Salk Institute, National Center for Microscopy Imaging Research, and Stanford University. A career pivot toward science policy led her to the California Legislature, where she worked for two years in the Senate Office of Research, including one year as a Science and Technology Policy Fellow. In that capacity, she covered several policy areas, including scientific research administration, public health, and developmental disabilities.

Throughout her career, Julianne established four public science education programs and directed the International “Brain Bee” Neuroscience Olympiad, a competition that engages over 50 countries. She was named International Student of the Year of Heidelberg University in 2011 and completed a Howard Hughes Medical Institute Med-Into-Grad Fellowship in 2010. As a Fulbright alumnus to Sweden, Julianne remains involved in the global alumni network as Co-Founder of TEDxFulbright.

Julianne earned a PhD in Neuroscience from Heidelberg University in Germany and a Masters degree in Biomedical Sciences from UC San Diego after graduating magna cum laude with a Bachelors degree in Neuroscience from Denison University.

Julianne McCall, PhDScience Officer, CIAPM, The California Governor’s Office of Planning & Research

Julianne McCall holds a PhD in Neuroscience with sixteen years of laboratory experience, including at the Salk Institute, National Center for Microscopy Imaging Research, and Stanford University. A career pivot toward science policy led her to the California Legislature, where she worked for two years in the Senate Office of Research, including one year as a Science and Technology Policy Fellow. In that capacity, she covered several policy areas, including scientific research administration, public health, and developmental disabilities.

Throughout her career, Julianne established four public science education programs and directed the International “Brain Bee” Neuroscience Olympiad, a competition that engages over 50 countries. She was named International Student of the Year of Heidelberg University in 2011 and completed a Howard Hughes Medical Institute Med-Into-Grad Fellowship in 2010. As a Fulbright alumnus to Sweden, Julianne remains involved in the global alumni network as Co-Founder of TEDxFulbright.

Julianne earned a PhD in Neuroscience from Heidelberg University in Germany and a Masters degree in Biomedical Sciences from UC San Diego after graduating magna cum laude with a Bachelors degree in Neuroscience from Denison University.

closepopup
Ysabel DuronFounder, Director, Latino Cancer Institute

Ysabel Duron is Founder and Executive Director of Latinas Contra Cancer. A cancer survivor herself, she founded Latinas Contra Cancer, in 2003 to address the void in services for Latinos around issues of cancer including support services and education, particularly in the low-income, Spanish-speaking community. Duron, a television journalist for over 39 years, was inducted into the National Association of Hispanic Journalists Hall of Fame in 2009. The San Jose Silicon Valley Business Journal named her a Women of Influence in 2008. She was named one of the most Influential Bay Area Latinos in 2005 by the San Francisco Hispanic Chamber. In 2003, she won the Janet Gray Hayes Award for her meritorious work as a journalist and as an advocate for Latinas with breast cancer. Duron was awarded The Purpose Prize in 2013 by Encore.org.

Ysabel DuronFounder, Director, Latino Cancer Institute

Ysabel Duron is Founder and Executive Director of Latinas Contra Cancer. A cancer survivor herself, she founded Latinas Contra Cancer, in 2003 to address the void in services for Latinos around issues of cancer including support services and education, particularly in the low-income, Spanish-speaking community. Duron, a television journalist for over 39 years, was inducted into the National Association of Hispanic Journalists Hall of Fame in 2009. The San Jose Silicon Valley Business Journal named her a Women of Influence in 2008. She was named one of the most Influential Bay Area Latinos in 2005 by the San Francisco Hispanic Chamber. In 2003, she won the Janet Gray Hayes Award for her meritorious work as a journalist and as an advocate for Latinas with breast cancer. Duron was awarded The Purpose Prize in 2013 by Encore.org.

closepopup
Felix Matthews, MD, MBAManaging Director, Deloitte

Felix is a managing director and physician leader at Deloitte Consulting LLP. He advises his clients on strategies to succeed in an increasingly competitive market. His clients include academic health centers, national health systems, health plans, and life sciences companies. He is experienced in corporate strategy, pre-deal strategic fit assessments, clinical affiliation strategy, care model innovation, value-based payments, operating model, physician engagement, and digital strategy, among others. He also advises his clients on strategy implementation and enabling capabilities.

With more than 15 years combined experience in medical practice and health care consulting, Felix brings to his clients a unique blend of clinical understanding and business insight. Felix trained in trauma surgery and accident medicine and has led research focused on clinical technology innovation at major academic centers in the United States and abroad. Felix is also a published author in peer-reviewed medical journals.

Felix Matthews, MD, MBAManaging Director, Deloitte

Felix is a managing director and physician leader at Deloitte Consulting LLP. He advises his clients on strategies to succeed in an increasingly competitive market. His clients include academic health centers, national health systems, health plans, and life sciences companies. He is experienced in corporate strategy, pre-deal strategic fit assessments, clinical affiliation strategy, care model innovation, value-based payments, operating model, physician engagement, and digital strategy, among others. He also advises his clients on strategy implementation and enabling capabilities.

With more than 15 years combined experience in medical practice and health care consulting, Felix brings to his clients a unique blend of clinical understanding and business insight. Felix trained in trauma surgery and accident medicine and has led research focused on clinical technology innovation at major academic centers in the United States and abroad. Felix is also a published author in peer-reviewed medical journals.

closepopup
Shyamali Singhal, MDDirector of Cancer Center, El Camino Hospital

Shyamali Singhal MD, is an accomplished Senior Executive and Thought Leader with more than 22 years of success across the healthcare industry. Leveraging extensive experience leading operations, clinical trials, quality control, and feedback, she is a valuable advisor for an organization implementing market strategies or positioning for growth. Her broad areas of expertise include oncology, medical devices, business strategy, business planning, and organizational leadership.

Throughout her executive career, Shyamali has held leadership positions with El Camino Hospital and Hope and Beauty.

Shyamali Singhal, MDDirector of Cancer Center, El Camino Hospital

Shyamali Singhal MD, is an accomplished Senior Executive and Thought Leader with more than 22 years of success across the healthcare industry. Leveraging extensive experience leading operations, clinical trials, quality control, and feedback, she is a valuable advisor for an organization implementing market strategies or positioning for growth. Her broad areas of expertise include oncology, medical devices, business strategy, business planning, and organizational leadership.

Throughout her executive career, Shyamali has held leadership positions with El Camino Hospital and Hope and Beauty.

closepopup
Hiroomi Tada MD PhDChief Medical Officer at Notable Labs

Hiroomi Tada, MD, PhD, oversees Notable’s clinical operations and brings decades of experience in cancer drug development to Notable. Surgical Oncologist and pharma veteran turned CMO, Tada is a specialist in translational science and clinical drug development, was most recently VP Targeted Therapies, Translational Sciences at Incyte Corporation, where he lead investigations of Incyte’s large targeted therapy portfolio in oncology. Prior to that, he was Medical Director, Oncology Clinical Development at GlaxoSmithKline and Director, Clinical Research at AstraZeneca. Tada is an M.D. who also has a PhD in Molecular Biology.

Hiroomi Tada MD PhDChief Medical Officer at Notable Labs

Hiroomi Tada, MD, PhD, oversees Notable’s clinical operations and brings decades of experience in cancer drug development to Notable. Surgical Oncologist and pharma veteran turned CMO, Tada is a specialist in translational science and clinical drug development, was most recently VP Targeted Therapies, Translational Sciences at Incyte Corporation, where he lead investigations of Incyte’s large targeted therapy portfolio in oncology. Prior to that, he was Medical Director, Oncology Clinical Development at GlaxoSmithKline and Director, Clinical Research at AstraZeneca. Tada is an M.D. who also has a PhD in Molecular Biology.

closepopup
Michael Gillam, MDFounder, CEO, HealthLab, Former Director, Microsoft Healthcare Innovation Lab

Michael Gillam, MD, FACEP, is CEO of HealthLab, a discovery automation company for “big data” and machine intelligence models. He has helped build and sell companies to WebMD and Microsoft and built a direct-to-consumer digital athletics company whose mobile app was called “game changing” by Apple and put in a commercial. He has served as a partner level executive in Microsoft and advised companies, health ministries and NGOs regarding their healthcare data strategies particularly in China and the Middle East. Dr. Gillam was research director for the big data aggregation solution, Azyxxi, which was acquired by Microsoft in 2006 to become one of their flagship products for healthcare, renamed Amalga He is a board certified emergency medicine physician who trained, practiced, and taught at Northwestern University in Chicago. He written over fifty papers and abstracts and has eleven patents in healthcare technology. He has served as Chair of Informatics for both the Society for Academic Emergency Medicine and the American College of Emergency Physicians. Dr. Gillam is a judge on the IBM AI XPrize, was the chief clinical judge for the Qualcomm Tricorder XPrize, and also served as a judge on the Nokia Sensing XPrize. Dr. Gillam founded and ran healthcare innovation labs for almost 10 years in Microsoft and in Washington D.C. and led projects spanning: predictive analytics; anomalous event detection; natural language processing (NLP); gesture based interfaces; de-identification; personal health records (PHRs); virtual & augmented reality; and medical robotics.

Michael Gillam, MDFounder, CEO, HealthLab, Former Director, Microsoft Healthcare Innovation Lab

Michael Gillam, MD, FACEP, is CEO of HealthLab, a discovery automation company for “big data” and machine intelligence models. He has helped build and sell companies to WebMD and Microsoft and built a direct-to-consumer digital athletics company whose mobile app was called “game changing” by Apple and put in a commercial. He has served as a partner level executive in Microsoft and advised companies, health ministries and NGOs regarding their healthcare data strategies particularly in China and the Middle East. Dr. Gillam was research director for the big data aggregation solution, Azyxxi, which was acquired by Microsoft in 2006 to become one of their flagship products for healthcare, renamed Amalga He is a board certified emergency medicine physician who trained, practiced, and taught at Northwestern University in Chicago. He written over fifty papers and abstracts and has eleven patents in healthcare technology. He has served as Chair of Informatics for both the Society for Academic Emergency Medicine and the American College of Emergency Physicians. Dr. Gillam is a judge on the IBM AI XPrize, was the chief clinical judge for the Qualcomm Tricorder XPrize, and also served as a judge on the Nokia Sensing XPrize. Dr. Gillam founded and ran healthcare innovation labs for almost 10 years in Microsoft and in Washington D.C. and led projects spanning: predictive analytics; anomalous event detection; natural language processing (NLP); gesture based interfaces; de-identification; personal health records (PHRs); virtual & augmented reality; and medical robotics.

closepopup
Mirella Lazarov, DDS, PhDHead of the Companion Diagnostics Center of Excellence (CDx COE) at AbbVie

Biomarkers and translational medicine leader with over 18 years of experience specializing in the areas of oncology, immunology and inflammation, ophthalmology, IBD, respiratory diseases, renal disease, and fibrosis. Strong background in the biotech and global pharmaceutical drug development process from target assessment through clinical development and approval. Expertise in managing products through various research and development stages, from inception through clinical trials. Proven ability to build, develop and manage cross-functional research, clinical development, biomarker and diagnostics teams in a matrix driven environment. Strong people management experience directing both small and large departments.

- Strong expertise in developing and implementing biomarker and companion diagnostics strategies from drug discovery through post-marketing activities across multiple therapeutic areas including oncology, immunology & inflammation, ophthalmology, fibrosis, virology, respiratory, and cardiovascular diseases.
- Successfully co-developed therapeutics with companion diagnostics, including Tarceva (erlotinib) for 1L NSCLC, Zelboraf (vemurafenib), and Onartuzumab (MetMab).
- Experienced in the discovery, development, validation and appropriate clinical utilization of biomarker assays, including pharmacodynamic, mechanism of action, safety, predictive, prognostic and monitoring biomarkers to be used as surrogate endpoints and/or as companion diagnostics.
- Strong scientific background in signal transduction, cellular pharmacology and molecular biology with peer reviewed scientific publications in Nature and Nature Medicine.
- Successfully built from the ground up and directed Preclinical Development, Development Sciences, Biomarker and Companion Diagnostics Departments in both start-up and mid-size Biotechnology companies

Job Related Accomplishements

- AbbVie: Established and leads the Companion Diagnostics Center of Excellence at Abbvie

Mirella Lazarov, DDS, PhDHead of the Companion Diagnostics Center of Excellence (CDx COE) at AbbVie

Biomarkers and translational medicine leader with over 18 years of experience specializing in the areas of oncology, immunology and inflammation, ophthalmology, IBD, respiratory diseases, renal disease, and fibrosis. Strong background in the biotech and global pharmaceutical drug development process from target assessment through clinical development and approval. Expertise in managing products through various research and development stages, from inception through clinical trials. Proven ability to build, develop and manage cross-functional research, clinical development, biomarker and diagnostics teams in a matrix driven environment. Strong people management experience directing both small and large departments.

- Strong expertise in developing and implementing biomarker and companion diagnostics strategies from drug discovery through post-marketing activities across multiple therapeutic areas including oncology, immunology & inflammation, ophthalmology, fibrosis, virology, respiratory, and cardiovascular diseases.
- Successfully co-developed therapeutics with companion diagnostics, including Tarceva (erlotinib) for 1L NSCLC, Zelboraf (vemurafenib), and Onartuzumab (MetMab).
- Experienced in the discovery, development, validation and appropriate clinical utilization of biomarker assays, including pharmacodynamic, mechanism of action, safety, predictive, prognostic and monitoring biomarkers to be used as surrogate endpoints and/or as companion diagnostics.
- Strong scientific background in signal transduction, cellular pharmacology and molecular biology with peer reviewed scientific publications in Nature and Nature Medicine.
- Successfully built from the ground up and directed Preclinical Development, Development Sciences, Biomarker and Companion Diagnostics Departments in both start-up and mid-size Biotechnology companies

Job Related Accomplishements

- AbbVie: Established and leads the Companion Diagnostics Center of Excellence at Abbvie

closepopup
Andrew Chacko, MD, MSEFounder & Principal at ChackoMD

Dr. J. Andrew Chacko is a leader in Healthcare Innovation. He is a highly sought after public-speaker and consultant on a broad array of topics from Design Thinking, Leadership, Healthcare, Education, Digital Health, Mental Health and Wellness. As the only practicing clinician to have graduated from the Stanford program that pioneered Design Thinking, he seamlessly knits together years of expertise in three seemingly disparate cultures.

He built his deep understanding of Healthcare through clinical experience as a psychiatrist, attending physician, medical director and clinic director. He became an expert in Design Thinking and Innovation, studying at its pioneering institution, the Product Design graduate program at Stanford, then working at IDEO and finally teaching these principles around the world, starting at Stanford. His hard-won acumen as a leader and team-builder began long before his admittance to the U.S. Naval Academy, and continued through his career as a Naval Officer and beyond. His singular mission is to help institutions and people transform the future of healthcare.
J. Andrew Chacko.USN.jpg

His unique perspective allows him to conceptualize the problems facing the healthcare industry from multiple angles. He passionately shares that ability with others through his advising and consultation work, and happily cultivates that awareness in clinicians, engineers, designers and entrepreneurs through his courses and lectures on how to implement Design Thinking and Leadership in Healthcare.

He is the founder of ChackoMD, a company he formed to drive Healthcare Innovation. As its principal, he has taught at universities, conferences and institutions around the world, from Stanford University, UC Berkeley, Tokyo University, for the American Psychiatric Association, the American Medical Association, to pharmaceutical companies, associations of medical education professionals and Google. He has also advised multiple healthcare institutions, numerous healthcare technology start-ups, including Pear Therapeutics, and design consultancies, and was faculty at NODE: Digital Health University, and Project Zygote, a Health 2.0 accelerator.

He is a Board-Certified Psychiatrist, now running a private clinic in San Francisco, recently having most recently worked for the VA, UCSF and Stanford, as a Medical Director and an attending Psychiatrist. He completed his training at Tripler Army Medical Center, where he was honored as the only civilian selected for a military psychiatry residency, gaining special expertise in PTSD and Traumatic Brain Injury.

He earned his MD from Tufts University School of Medicine. He is a graduate of the U. S. Naval Academy, and served 12 years in the Navy, before completing his post-baccalaureate studies through Harvard. He earned his graduate degree at Stanford, studying both Mechanical Engineering and Art in the Joint Program in Design, taking an extra year for an in depth focus on Robotics, working as a designer independently and at IDEO.

He is an accomplished artist in wood-working, painting, and graphic design, and enjoys making just about anything from robots to furniture. His work has been galleried and sold. He loves dancing, has won dance competitions and is a certified Zumba Instructor. He is a certified military parachutist and rescue diver. He loves travel and exploring other cultures, having studied French, Spanish and Japanese. His biggest passion, however, is teaching (which he has done in some form since high-school) and drawing out human potential. His audiences have called him inspiring to life-changing. One of his favorite compliments came from a security guard at a lecture on the difficulties of innovating in healthcare, who later said that he “loved it so much [he] took notes the whole time!”

Andrew Chacko, MD, MSEFounder & Principal at ChackoMD

Dr. J. Andrew Chacko is a leader in Healthcare Innovation. He is a highly sought after public-speaker and consultant on a broad array of topics from Design Thinking, Leadership, Healthcare, Education, Digital Health, Mental Health and Wellness. As the only practicing clinician to have graduated from the Stanford program that pioneered Design Thinking, he seamlessly knits together years of expertise in three seemingly disparate cultures.

He built his deep understanding of Healthcare through clinical experience as a psychiatrist, attending physician, medical director and clinic director. He became an expert in Design Thinking and Innovation, studying at its pioneering institution, the Product Design graduate program at Stanford, then working at IDEO and finally teaching these principles around the world, starting at Stanford. His hard-won acumen as a leader and team-builder began long before his admittance to the U.S. Naval Academy, and continued through his career as a Naval Officer and beyond. His singular mission is to help institutions and people transform the future of healthcare.
J. Andrew Chacko.USN.jpg

His unique perspective allows him to conceptualize the problems facing the healthcare industry from multiple angles. He passionately shares that ability with others through his advising and consultation work, and happily cultivates that awareness in clinicians, engineers, designers and entrepreneurs through his courses and lectures on how to implement Design Thinking and Leadership in Healthcare.

He is the founder of ChackoMD, a company he formed to drive Healthcare Innovation. As its principal, he has taught at universities, conferences and institutions around the world, from Stanford University, UC Berkeley, Tokyo University, for the American Psychiatric Association, the American Medical Association, to pharmaceutical companies, associations of medical education professionals and Google. He has also advised multiple healthcare institutions, numerous healthcare technology start-ups, including Pear Therapeutics, and design consultancies, and was faculty at NODE: Digital Health University, and Project Zygote, a Health 2.0 accelerator.

He is a Board-Certified Psychiatrist, now running a private clinic in San Francisco, recently having most recently worked for the VA, UCSF and Stanford, as a Medical Director and an attending Psychiatrist. He completed his training at Tripler Army Medical Center, where he was honored as the only civilian selected for a military psychiatry residency, gaining special expertise in PTSD and Traumatic Brain Injury.

He earned his MD from Tufts University School of Medicine. He is a graduate of the U. S. Naval Academy, and served 12 years in the Navy, before completing his post-baccalaureate studies through Harvard. He earned his graduate degree at Stanford, studying both Mechanical Engineering and Art in the Joint Program in Design, taking an extra year for an in depth focus on Robotics, working as a designer independently and at IDEO.

He is an accomplished artist in wood-working, painting, and graphic design, and enjoys making just about anything from robots to furniture. His work has been galleried and sold. He loves dancing, has won dance competitions and is a certified Zumba Instructor. He is a certified military parachutist and rescue diver. He loves travel and exploring other cultures, having studied French, Spanish and Japanese. His biggest passion, however, is teaching (which he has done in some form since high-school) and drawing out human potential. His audiences have called him inspiring to life-changing. One of his favorite compliments came from a security guard at a lecture on the difficulties of innovating in healthcare, who later said that he “loved it so much [he] took notes the whole time!”

closepopup
Anupam Agarwal, MDVP, Harvard Club SF, VP, Zogenix Inc.

Anupam Agarwal MD is the Vice President and global head of safety & pharmacovigilance at Zogenix Inc. He is a cardiologist by training with over two decades of experience in treating patients and clinical research in academia. He is working in the pharmaceutical industry for more than 12 years. He was involved with research in the genetics of hypertension; drug eluted coronary stents at Brigham and Women’s Hospital, Harvard Medical School.
Anupam holds a medical degree from the GSVM Medical College, Kanpur, India and a Master of Public Health degree from the Harvard School of Public Health. He is a member of scientific oversight committee at the Cardiac Safety Research Consortium (CSRC) a think tank which was launched through an FDA Critical Path Initiative with Duke University to support research into the evaluation of cardiac safety of medical products.

Anupam Agarwal, MDVP, Harvard Club SF, VP, Zogenix Inc.

Anupam Agarwal MD is the Vice President and global head of safety & pharmacovigilance at Zogenix Inc. He is a cardiologist by training with over two decades of experience in treating patients and clinical research in academia. He is working in the pharmaceutical industry for more than 12 years. He was involved with research in the genetics of hypertension; drug eluted coronary stents at Brigham and Women’s Hospital, Harvard Medical School.
Anupam holds a medical degree from the GSVM Medical College, Kanpur, India and a Master of Public Health degree from the Harvard School of Public Health. He is a member of scientific oversight committee at the Cardiac Safety Research Consortium (CSRC) a think tank which was launched through an FDA Critical Path Initiative with Duke University to support research into the evaluation of cardiac safety of medical products.

closepopup
Uli K. Chettipally, MD.Founder InnovatorMD, Former Kaiser Permanente

Dr. Chettipally is a speaker, emergency physician, researcher, and an innovator, founder of InnovatorMD. He is passionate about the technology-enabled care that can decrease the burden on physicians and increase the value for patients. As the Co-founder and Chief Technology Officer of CREST Network, he designed, developed and implemented a clinical decision support platform to deliver real-time guidance at the point of care, to decrease the cognitive burden on physicians and improve patient outcomes in 21 hospitals. He received the "Pioneer Award" from Kaiser Permanente Innovations and "Morris F. Collen Research Award" from The Permanente Medical Group for his groundbreaking work. His other roles include President, Society of Physician Entrepreneurs, San Francisco Bay Area chapter; Assistant Clinical Professor of Medicine at the University of California, San Francisco; and is the Secretary/Treasurer, San Mateo County Medical Association.

Uli K. Chettipally, MD.Founder InnovatorMD, Former Kaiser Permanente

Dr. Chettipally is a speaker, emergency physician, researcher, and an innovator, founder of InnovatorMD. He is passionate about the technology-enabled care that can decrease the burden on physicians and increase the value for patients. As the Co-founder and Chief Technology Officer of CREST Network, he designed, developed and implemented a clinical decision support platform to deliver real-time guidance at the point of care, to decrease the cognitive burden on physicians and improve patient outcomes in 21 hospitals. He received the "Pioneer Award" from Kaiser Permanente Innovations and "Morris F. Collen Research Award" from The Permanente Medical Group for his groundbreaking work. His other roles include President, Society of Physician Entrepreneurs, San Francisco Bay Area chapter; Assistant Clinical Professor of Medicine at the University of California, San Francisco; and is the Secretary/Treasurer, San Mateo County Medical Association.

closepopup
Alan S. Young, MD, MBA, PMPChief Medical Officer, GYANT

Dr. Alan Young is a physician leader with strong clinical and business accomplishments. After completing a dual MD/MBA degree program at USC's Keck School of Medicine & Marshall School of Business, he obtained his medical license during his Orthopedic Surgery residency. Combining his passion for business & medicine, he served as a national healthcare subject matter expert Specialist Senior Consultant with Deloitte Consulting while providing surgical physician services at Southern California Kaiser Permanente. At USC Care Medical Group he was the Director of Operations Strategy and Special Projects, leading ambulatory quality improvement initiatives and electronic health record optimization efforts to improve both patient and physician engagement. He served as the Regional Director of Client Relations with Sagacious Consultants and Senior Manager with Accenture to drive business development for EPIC EMR solutions and recently was the Client Service Leader for Slalom Consulting in LA building their healthcare and life sciences portfolio while working with large health systems and insurance companies. Currently, he is the Chief Medical Officer for Gyant, an artificial intelligence powered software company working to engage patients and providers. He is a regular speaker and moderator for HIMSS, Health Care Executives and AI Med as well as a contributing author to a text book on Digital Health Entrepreneurship.
His clinical experience spans across Orthopedic/General Surgery, Emergency Medicine, Urgent Care, outpatient ambulatory clinics, specialty pediatric hospitals, HMO and VA hospitals. International health experience includes completion of a clinical elective program at the National Taiwan University School of Medicine in Orthopedics as well as two volunteer medical missions trips to Cambodia and Haiti. He currently practices medicine in the greater Los Angeles area and he also serves as the So Cal HIMSS CMIO Committee Chair, Society of Physician Entrepreneurs LA Chapter Leader, AIMed Ambassador and a ScaleLA Healthcare Committee member.

Alan S. Young, MD, MBA, PMPChief Medical Officer, GYANT

Dr. Alan Young is a physician leader with strong clinical and business accomplishments. After completing a dual MD/MBA degree program at USC's Keck School of Medicine & Marshall School of Business, he obtained his medical license during his Orthopedic Surgery residency. Combining his passion for business & medicine, he served as a national healthcare subject matter expert Specialist Senior Consultant with Deloitte Consulting while providing surgical physician services at Southern California Kaiser Permanente. At USC Care Medical Group he was the Director of Operations Strategy and Special Projects, leading ambulatory quality improvement initiatives and electronic health record optimization efforts to improve both patient and physician engagement. He served as the Regional Director of Client Relations with Sagacious Consultants and Senior Manager with Accenture to drive business development for EPIC EMR solutions and recently was the Client Service Leader for Slalom Consulting in LA building their healthcare and life sciences portfolio while working with large health systems and insurance companies. Currently, he is the Chief Medical Officer for Gyant, an artificial intelligence powered software company working to engage patients and providers. He is a regular speaker and moderator for HIMSS, Health Care Executives and AI Med as well as a contributing author to a text book on Digital Health Entrepreneurship.
His clinical experience spans across Orthopedic/General Surgery, Emergency Medicine, Urgent Care, outpatient ambulatory clinics, specialty pediatric hospitals, HMO and VA hospitals. International health experience includes completion of a clinical elective program at the National Taiwan University School of Medicine in Orthopedics as well as two volunteer medical missions trips to Cambodia and Haiti. He currently practices medicine in the greater Los Angeles area and he also serves as the So Cal HIMSS CMIO Committee Chair, Society of Physician Entrepreneurs LA Chapter Leader, AIMed Ambassador and a ScaleLA Healthcare Committee member.

closepopup
Pritmohinder Gill, PhDAssociate Professor, Arkansas Children’s Research Institute, UAMS

Pritmohinder Gill, PhD, received his PhD in Biological Anthropology from Southern Illinois University, Carbondale and has over 25 years of expertise studying human genetics. Dr. Gill joined ACRI in November 2012 and his research interests include the use of omic- technologies in discovering novel and sensitive biomarkers in human disease.

Under the direction of Dr. Schaefer, Dr. Gill will head the pediatric experimental therapeutics and precision medicine programs to aid in molecular profiling for patients with difficult conditions. The goal is to better target therapies for children with challenging diseases.

Dr. Gill is also interested in the role of miRNAs in the development of autism spectrum disorder (Dr. Shannon Rose) and acetaminophen drug toxicity (Dr. Laura James).

Dr. Gill’s work aims to advance the current knowledge of epigenetic involvement in diseases and understand interactions that influence genetic regulation. This will help the translation of basic discoveries to identify novel targets for drug development and better therapeutic intervention.

Pritmohinder Gill, PhDAssociate Professor, Arkansas Children’s Research Institute, UAMS

Pritmohinder Gill, PhD, received his PhD in Biological Anthropology from Southern Illinois University, Carbondale and has over 25 years of expertise studying human genetics. Dr. Gill joined ACRI in November 2012 and his research interests include the use of omic- technologies in discovering novel and sensitive biomarkers in human disease.

Under the direction of Dr. Schaefer, Dr. Gill will head the pediatric experimental therapeutics and precision medicine programs to aid in molecular profiling for patients with difficult conditions. The goal is to better target therapies for children with challenging diseases.

Dr. Gill is also interested in the role of miRNAs in the development of autism spectrum disorder (Dr. Shannon Rose) and acetaminophen drug toxicity (Dr. Laura James).

Dr. Gill’s work aims to advance the current knowledge of epigenetic involvement in diseases and understand interactions that influence genetic regulation. This will help the translation of basic discoveries to identify novel targets for drug development and better therapeutic intervention.

closepopup
Rajiv PratapChief Business Officer at Abzooba Inc.

Alumnus of the prestigious IBM T.J. Watson Research Lab, Rajiv has over 23 years of experience with creating disruptive value with data and analytics. His areas of expertise include AI, Deep Learning, Big Data, Predictive Analytics, innovative Big Data architecture, and deriving disruptive value from large amounts of structured and unstructured data. In his current role at Abzooba Inc, Rajiv is creating innovative technologies and products in conversational intelligence and bots with nuanced cognitive understanding of language (textual and speech), and vision. Rajiv owns Abzooba's flagship offering called xpresso.ai - a platform that provides cognitive bots that use Artificial Intelligence, Deep Learning, Natural Language Understanding, Computer Vision and other leading edge and technologies to empower consumers and enterprises cognitively.

His area of expertise encompasses innovative and ground-breaking work in the field of Artificial Intelligence, Deep Learning, Data mining and business intelligence architecture using latest technologies to deliver cognitive analytics, decision support tools and actionable knowledge to end-users over the Internet. Mr. Pratap has co-authored several pioneering technical papers/research reports for very prestigious publications and two international patents.

Rajiv was a founding member of Virtual Gold, Inc. (www.virtualgold.com) , a NY based data mining and BI company, and Avita Software Pvt. Ltd. He also served as the CTO of ChiMatrix, LLC (www.avitasoftware.com), a NY based company that focused on electronic data capture and advanced analytics for the pharmaceutical domain.

Rajiv has been educated at the Indian Institute of Technology, Kanpur, India (B. Tech., Computer Science, 1993).

Specialties: AI, Machine Learning, Deep Learning, Big Data, Knowledge discovery, data mining, advanced analytics, cognitive workflow automation for sales and marketing enablement.

Rajiv PratapChief Business Officer at Abzooba Inc.

Alumnus of the prestigious IBM T.J. Watson Research Lab, Rajiv has over 23 years of experience with creating disruptive value with data and analytics. His areas of expertise include AI, Deep Learning, Big Data, Predictive Analytics, innovative Big Data architecture, and deriving disruptive value from large amounts of structured and unstructured data. In his current role at Abzooba Inc, Rajiv is creating innovative technologies and products in conversational intelligence and bots with nuanced cognitive understanding of language (textual and speech), and vision. Rajiv owns Abzooba's flagship offering called xpresso.ai - a platform that provides cognitive bots that use Artificial Intelligence, Deep Learning, Natural Language Understanding, Computer Vision and other leading edge and technologies to empower consumers and enterprises cognitively.

His area of expertise encompasses innovative and ground-breaking work in the field of Artificial Intelligence, Deep Learning, Data mining and business intelligence architecture using latest technologies to deliver cognitive analytics, decision support tools and actionable knowledge to end-users over the Internet. Mr. Pratap has co-authored several pioneering technical papers/research reports for very prestigious publications and two international patents.

Rajiv was a founding member of Virtual Gold, Inc. (www.virtualgold.com) , a NY based data mining and BI company, and Avita Software Pvt. Ltd. He also served as the CTO of ChiMatrix, LLC (www.avitasoftware.com), a NY based company that focused on electronic data capture and advanced analytics for the pharmaceutical domain.

Rajiv has been educated at the Indian Institute of Technology, Kanpur, India (B. Tech., Computer Science, 1993).

Specialties: AI, Machine Learning, Deep Learning, Big Data, Knowledge discovery, data mining, advanced analytics, cognitive workflow automation for sales and marketing enablement.

closepopup
Mark PunyanityaFounder and CEO PhenoMX

Mark Punyanitya is a Biomedical Engineer with advanced degrees in Applied Physiology & Applied Clinical Trials. He facilitates the translation of science, technology, & medicine for development & commercialization of innovative technologies.

Co-Founder, President, & CEO of PhenoMx, Inc.: commercializing a Digital Physical Exam as an imaging platform that provides clinical & quantitative screening/diagnostic imaging to non-radiologists via extending these capabilities beyond the hospital into the community, to address the digital divide, health disparities, and social determinants of health.

With over 20 years experience implementing & standardizing medical imaging, Mark has published over 40 papers & his advances in body composition have been applied to a wide range of therapeutic areas.

Mark PunyanityaFounder and CEO PhenoMX

Mark Punyanitya is a Biomedical Engineer with advanced degrees in Applied Physiology & Applied Clinical Trials. He facilitates the translation of science, technology, & medicine for development & commercialization of innovative technologies.

Co-Founder, President, & CEO of PhenoMx, Inc.: commercializing a Digital Physical Exam as an imaging platform that provides clinical & quantitative screening/diagnostic imaging to non-radiologists via extending these capabilities beyond the hospital into the community, to address the digital divide, health disparities, and social determinants of health.

With over 20 years experience implementing & standardizing medical imaging, Mark has published over 40 papers & his advances in body composition have been applied to a wide range of therapeutic areas.

closepopup
Sam King, MPHCOO at Medical Intelligence 10 (mi10)

Sam King MPH is an accomplished healthcare executive, faculty and consultant with unique combination of expertise in healthcare finance, healthcare IT, analytics, artificial intelligence, project management, financial planning and analysis, and continuous quality improvement; Strong leadership capability, exceptional organizational and project management skills with proven track record; Effective communication skills to manage expectations of internal and external clients, including physicians, clinicians, government agents and business executives; Demonstrated ability to manage project, direct and motivate multi-functional, multi-divisional teams; A frequent, internationally recognized speaker/moderator concerning current issues and challenges impacting health policy, healthcare IT, healthcare finance and quality.

Roles: CIO, COO, VP of Analytics, Director of Medical/Healthcare Informatics, Senior Director of Professional Development

Specialties: Healthcare Finance, Health IT, Artificial Intelligence, Big Data and Analytics, Process/Quality Improvement, Artifitial Intelligence, and Project Management

Sam King, MPHCOO at Medical Intelligence 10 (mi10)

Sam King MPH is an accomplished healthcare executive, faculty and consultant with unique combination of expertise in healthcare finance, healthcare IT, analytics, artificial intelligence, project management, financial planning and analysis, and continuous quality improvement; Strong leadership capability, exceptional organizational and project management skills with proven track record; Effective communication skills to manage expectations of internal and external clients, including physicians, clinicians, government agents and business executives; Demonstrated ability to manage project, direct and motivate multi-functional, multi-divisional teams; A frequent, internationally recognized speaker/moderator concerning current issues and challenges impacting health policy, healthcare IT, healthcare finance and quality.

Roles: CIO, COO, VP of Analytics, Director of Medical/Healthcare Informatics, Senior Director of Professional Development

Specialties: Healthcare Finance, Health IT, Artificial Intelligence, Big Data and Analytics, Process/Quality Improvement, Artifitial Intelligence, and Project Management

closepopup
Andre WatsonFounder, CEO Ligandal

Andre founded Ligandal to enable programming of biological matter with nanomaterials, ultimately with the aim of extending human lives and creating curative genomic therapies. While studying Biomedical Engineering and Biomaterials at RPI, he created a proof of concept for Ligandal's nanoparticle-based gene delivery platform, and the world’s first non-viral system for delivering guided nucleases in vivo. Andre created the proof of concept for the first technology capable of cell-specifically targeting gene editing constructs. Andre splits his attention between financing, business development, IP and designing biomimetic nanoparticle architectures. His vision for Ligandal is to enable a new era in personalized medicine and globally accessible gene therapy.

Andre WatsonFounder, CEO Ligandal

Andre founded Ligandal to enable programming of biological matter with nanomaterials, ultimately with the aim of extending human lives and creating curative genomic therapies. While studying Biomedical Engineering and Biomaterials at RPI, he created a proof of concept for Ligandal's nanoparticle-based gene delivery platform, and the world’s first non-viral system for delivering guided nucleases in vivo. Andre created the proof of concept for the first technology capable of cell-specifically targeting gene editing constructs. Andre splits his attention between financing, business development, IP and designing biomimetic nanoparticle architectures. His vision for Ligandal is to enable a new era in personalized medicine and globally accessible gene therapy.

closepopup
Douglas Zhang, MD, MBAPhysician and Managing Partner FMG

Dr. Douglas Zhang, MD is a family medicine specialist in San Leandro, CA and has been practicing for 25 years. He graduated from Texas Tech University Health Sciences Center School Of Medicine in 1994 and specializes in family medicine.

Douglas Zhang, MD, MBAPhysician and Managing Partner FMG

Dr. Douglas Zhang, MD is a family medicine specialist in San Leandro, CA and has been practicing for 25 years. He graduated from Texas Tech University Health Sciences Center School Of Medicine in 1994 and specializes in family medicine.

closepopup
Ramesh Hariharan, PhD, MBAGeneral Manager of Women's Health business at Natera

Dr. Ramesh Hariharan’s career of 18 years spans a rage of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. Most recently at Biotheranostics, he drove the successful commercial turnaround and relaunch of Breast Cancer Index and CancerTYPE ID including repositioning, branding, messaging, and targeted promotions to medical oncologists and patients. He received a bachelor’s degree in chemical engineering from IIT Bombay, a Ph.D. in chemical engineering from Princeton University, and an M.B.A. from MIT Sloan School of Management.

Ramesh Hariharan, PhD, MBAGeneral Manager of Women's Health business at Natera

Dr. Ramesh Hariharan’s career of 18 years spans a rage of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated as the Best Young Scientist for his innovations, which included the discovery of a new molecule that was commercialized to enable higher data densities in rewritable DVDs, and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostics, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, and Vaccines at Novartis, Abbott/AbbVie and Biotheranostics. Most recently at Biotheranostics, he drove the successful commercial turnaround and relaunch of Breast Cancer Index and CancerTYPE ID including repositioning, branding, messaging, and targeted promotions to medical oncologists and patients. He received a bachelor’s degree in chemical engineering from IIT Bombay, a Ph.D. in chemical engineering from Princeton University, and an M.B.A. from MIT Sloan School of Management.

closepopup
Sanjeev Jain, MD, PhDCEO, The Columbia Asthma & Allergy Clinic

Educated in allergy and immunology at Yale University, Dr. Jain first received a joint MD and PhD from the University of Wisconsin and finished his residency at the University of Texas. He then taught and practiced at the University of Washington Medical School in Seattle, where he developed a reputation as one of the finest allergists in the region. He has won numerous awards and is included in the Guide to America’s Top Physicians consistently for last several years.
As an allergist, Dr. Jain treasures the opportunity to witness his patients make dramatic improvements after years of suffering.
He can recall several instances where his patients who had previously required repeated hospital admissions for asthma exacerbations have returned to normal lives free of hospitalizations. In Dr. Jain’s experience, most patients can achieve significant improvements by determining the individual triggers of their allergic reactions and by instituting an appropriate therapy. “Any type of symptom, is not acceptable.”
Dr. Jain’s OIT experience spans back to 2007. He has developed protocols that permit a patient to move through the entire desensitization process with little to no side effects using little to no additional medications. In simple terms, Dr. Jain can treat any food allergy and is one of the few OIT Allergists to offer SLIT therapy as well as traditional OIT.

Sanjeev Jain, MD, PhDCEO, The Columbia Asthma & Allergy Clinic

Educated in allergy and immunology at Yale University, Dr. Jain first received a joint MD and PhD from the University of Wisconsin and finished his residency at the University of Texas. He then taught and practiced at the University of Washington Medical School in Seattle, where he developed a reputation as one of the finest allergists in the region. He has won numerous awards and is included in the Guide to America’s Top Physicians consistently for last several years.
As an allergist, Dr. Jain treasures the opportunity to witness his patients make dramatic improvements after years of suffering.
He can recall several instances where his patients who had previously required repeated hospital admissions for asthma exacerbations have returned to normal lives free of hospitalizations. In Dr. Jain’s experience, most patients can achieve significant improvements by determining the individual triggers of their allergic reactions and by instituting an appropriate therapy. “Any type of symptom, is not acceptable.”
Dr. Jain’s OIT experience spans back to 2007. He has developed protocols that permit a patient to move through the entire desensitization process with little to no side effects using little to no additional medications. In simple terms, Dr. Jain can treat any food allergy and is one of the few OIT Allergists to offer SLIT therapy as well as traditional OIT.

closepopup
Subhadra Dravida, PhDFounder and CEO, Transcell Biologics

Subhadra Dravida, PhD is the founder CEO of Transcell Biologics Pvt. Ltd www.transcellbio.science, innovating new vistas in healthcare/biotechnology industry and markets from India. She is an entrepreneurial technocrat of global standing having worked in the USA, Canada and India in the domains of stem cell research/biobanking and product development. She has unique blend of skills of wet lab, product development to managing business. Under her stewardship, Transcell Biologics, a knowledge driven technology intensive entity has evolved from its inception as an R&D unit to a fully integrated biotechnology enterprise encompassing a well balanced business portfolio offering indigenous technologies on biobanking and processing services with drug discovery research integrating regenerative medicine into clinical practice.
She is a biologist by education with clinical informatics research experience having associated professionally with the University of North Carolina, USA, Ottawa Health Research Institute, Canada. S Dravida has peer reviewed publications and patents to her credit and was nominated for global women in leadership award in 2011 in science, recipient of 2012, Small Business Industrial Research award to develop dental stem cell products/processes in implantology, MSME award to conduct research on lacrimal gland regeneration to address dry eye syndrome, PPMD support to craft stem cell treatment protocols treating Muscular Dystrophies, in 2012-14. She is the recipient of 2017 Lady Entrepreneur Award given by GOI. She holds IP in the field of large scale cell productions & novel druggable formulations. Outside of work, she explores Monasteries, night skies and reads Science fiction.

Subhadra Dravida, PhDFounder and CEO, Transcell Biologics

Subhadra Dravida, PhD is the founder CEO of Transcell Biologics Pvt. Ltd www.transcellbio.science, innovating new vistas in healthcare/biotechnology industry and markets from India. She is an entrepreneurial technocrat of global standing having worked in the USA, Canada and India in the domains of stem cell research/biobanking and product development. She has unique blend of skills of wet lab, product development to managing business. Under her stewardship, Transcell Biologics, a knowledge driven technology intensive entity has evolved from its inception as an R&D unit to a fully integrated biotechnology enterprise encompassing a well balanced business portfolio offering indigenous technologies on biobanking and processing services with drug discovery research integrating regenerative medicine into clinical practice.
She is a biologist by education with clinical informatics research experience having associated professionally with the University of North Carolina, USA, Ottawa Health Research Institute, Canada. S Dravida has peer reviewed publications and patents to her credit and was nominated for global women in leadership award in 2011 in science, recipient of 2012, Small Business Industrial Research award to develop dental stem cell products/processes in implantology, MSME award to conduct research on lacrimal gland regeneration to address dry eye syndrome, PPMD support to craft stem cell treatment protocols treating Muscular Dystrophies, in 2012-14. She is the recipient of 2017 Lady Entrepreneur Award given by GOI. She holds IP in the field of large scale cell productions & novel druggable formulations. Outside of work, she explores Monasteries, night skies and reads Science fiction.

closepopup
Manoj KenkareManaging Director, Accenture

Manoj Kenkare is a seasoned executive and most Trusted advisor. He is well networked executive within SF bay area with relationships in North America and beyond. During his career Manoj has worked on several transformation deals with Fortune 100 companies and some key institutions like The Whitehouse, FDA, NIH and CDC. Key areas of focus Strategy, AI, SAP/Oracle/ERP applications, Analytics and Data Sciences, Mobility, Workday, Cloud and Portal strategies among others.

Manoj KenkareManaging Director, Accenture

Manoj Kenkare is a seasoned executive and most Trusted advisor. He is well networked executive within SF bay area with relationships in North America and beyond. During his career Manoj has worked on several transformation deals with Fortune 100 companies and some key institutions like The Whitehouse, FDA, NIH and CDC. Key areas of focus Strategy, AI, SAP/Oracle/ERP applications, Analytics and Data Sciences, Mobility, Workday, Cloud and Portal strategies among others.

closepopup
Doug Milikien, MSPrincipal Consulting Biostatistician, NCC-ACRP

Involved in pharmaceutical, medical device, biologics, and diagnostic development for over 25 years, Doug began his postgraduate career as a Research Statistician with the Northern California Alzheimer’s Disease Center. After two years working for a statistical consulting firm, Doug founded Accudata Solutions in 1991. He has led or participated in numerous regulatory submissions and successfully interacted with regulatory bodies, including submissions for digital health and AI-driven products. Doug has served as a voting member of a Data Safety Monitoring Board and served as instructor to pharmaceutical scientists at the Institute for International Research as well as in-house instructor to the biotechnology division of a large, multinational pharmaceutical company. Doug serves as the statistics Subject Matter Expert and advisor for 2 mentoring programs offering guidance to start-up biotech and medical technology companies: a.) the California Life Science Institute’s FAST program, b.) and Canadian Technology Accelerator- San Francisco. He is the author of numerous peer-reviewed articles. Doug holds advanced degrees in Biostatistics and Demography, both from the University of California, Berkeley.

Doug Milikien, MSPrincipal Consulting Biostatistician, NCC-ACRP

Involved in pharmaceutical, medical device, biologics, and diagnostic development for over 25 years, Doug began his postgraduate career as a Research Statistician with the Northern California Alzheimer’s Disease Center. After two years working for a statistical consulting firm, Doug founded Accudata Solutions in 1991. He has led or participated in numerous regulatory submissions and successfully interacted with regulatory bodies, including submissions for digital health and AI-driven products. Doug has served as a voting member of a Data Safety Monitoring Board and served as instructor to pharmaceutical scientists at the Institute for International Research as well as in-house instructor to the biotechnology division of a large, multinational pharmaceutical company. Doug serves as the statistics Subject Matter Expert and advisor for 2 mentoring programs offering guidance to start-up biotech and medical technology companies: a.) the California Life Science Institute’s FAST program, b.) and Canadian Technology Accelerator- San Francisco. He is the author of numerous peer-reviewed articles. Doug holds advanced degrees in Biostatistics and Demography, both from the University of California, Berkeley.

closepopup
David Purdie, PhDVice President, Proteus Digital Health

David Purdie, PhD is VP at Proteus Digital Health. Prior to Proteus he was at Genentech Roche, where he served as the head of quality of care and patient access as well as director of BioOncology commercial training and development. He was also a lecture at Stanford.

David Purdie, PhDVice President, Proteus Digital Health

David Purdie, PhD is VP at Proteus Digital Health. Prior to Proteus he was at Genentech Roche, where he served as the head of quality of care and patient access as well as director of BioOncology commercial training and development. He was also a lecture at Stanford.

closepopup

Schedule

AAPM 2021 Annual Meeting Plenary Session

  • January 8th
  • January 7th
  • Theater
08:00 AM - 08:15 AMWelcome: AAPM Annual Meeting 2021 By VariousClinical Trials
Welcoming notes by MC
Introduction: Prasun J Mishra, Ph.D., Founder and CEO AAPM, Chair, ACT: AAPM Coronavirus Taskforce

 

 

08:15 AM - 09:30 AMOpening Panel: Scaling Precision Medicine Globally By Various Investor's perspective

Moderator: Nazneen Aziz, Ph.D., CSO at Avellino Lab

  • Olamide Hakeem Adejumo, Co-founder, The Nigeria Diabetes Community
  • Panna Sharma, CEO, Lantern Pharma
  • Anoop Ambika, MBA, CEO, CLAP Research & Genpro Research
  • Amit Bansal, Founder, CEO at Diya Health Inc.

 

 

09:30 AM - 10:45 AMOpening Keynotes: Driving the Future of Precision Medicine By VariousTech and Precision Medicine
Moderator: Prasun J Mishra, Ph.D., Founder and CEO AAPM
  • Shannon Muir, Ph.D., Co-Director California Initiative to Advance Precision Medicine, California Governor’s Office.
  • Lynda Chin, Founder, President and CEO, Apricity Health, Adjunct Professor, Dell Medical School
  • Sumeet Bhatia, MD, MBBS, President, Community Hospital Oncology Physicians
  • Erika Brown, CEO/Co-Founder PALTOWN Development Foundation, Patient Advocate
10:45 AM - 11:15 AMFireside Chat: Implementing Value‐Based Health Care at Scale By VariousTech and Precision Medicine
  • John Mattison, MD., Emeritus Asst. Med Director, and Chief Medical Information Officer, Kaiser Permanente in conversation with
  • Prasun J Mishra, Ph.D., Founder and CEO AAPM

 

11:15 AM - 12:00 PMLightning Talks: AAPM2021 By VariousTech and Precision Medicine

Moderator: Suraj Saksena, PhD., Science and Technology Leader, BD

  • Yan Leyfman, Director Immunology, WACEM-ACAIM COVID-19 Taskforce
  • Sanket Mishra, MPharma, MS, PhD., Co-founder Grannus Therapeutics
  • Jimmy Qian, Co-founder and COO, Osmind, Stanford University
  • Brisa Fernandes, MD, PhD., The University of Texas Health Science Center
  • Amreen Khan, MTech, Researcher, Indian Institute of Technology
  • Krish Chakrabarti, MBA, Head Risk, and BD, Medical iSight
12:00 PM - 01:00 PMWomen Diversity in Precision Medicine By VariousWomen in Precision Medicine

Moderator: Reem Mahrat, Founder and CEO Calico BioLabs, Director AAPM

  • Irina Meyer, Founder and Managing Partner of Sils Capital Venture Fund
  • Linda Ellison, Ph.D., Harvard University, Founder and CEO of kaü Health, Former Managing Director, United Nations
  • Nivedita Lakhera, MD, Internal Medicine – Hospitalist, and Author
  • Kamala K Maddali DVM Ph.D., President, Health Collaborations, VP, Deep Lens
01:00 PM - 01:45 PMClosing Keynotes: How Precision Medicine is Improving Quality of Care By VariousPrecision Health

Moderator: Prasun J Mishra, Ph.D., Founder and CEO AAPM

  • Kristine Ashcraft, MBA, Head of Pharmacogenomics, Invitae, Former CEO, YouScript
  • Luigi Fontana, MD, Ph.D., FRACP, Director, Healthy Longevity Program at Charles Perkins Centre, University of Sydney
  • Daniel J. Mueller, MD, Ph.D., Professor, University of Toronto
  • Santhosh Balasubramanian, Director, Notable Labs
  • Ron Lanton III, JD, Esq Principal Lanton Law, Chair, Biologics Committee, New York State Bar Association
01:45 PM - 02:00 PMClosing Remarks and Conclusion By VariousTech and Precision Medicine

Prasun J Mishra, Ph.D., Founder and CEO AAPM

  • Theater
08:00 AM - 08:15 AMWelcome: DataAI National Summit (DANS2021) By VariousData and PM
Welcoming notes by MC
Introduction: Prasun J Mishra, Ph.D., Founder and CEO AAPM
08:15 AM - 09:30 AMOpening Session: Investment landscape in DataAI and Healthcare Sector By VariousInvestor's perspective

Moderator: Jay Chen, VC, Partner, Hope Venture Labs

  • Sanjit Singh Dang, Ph.D. Co-founder, Chairman, U First Capital, Ex-IntelCapital VC
  • Irina Meyer, Founder and Managing Partner of Sils Capital Venture Fund
  • Justin Ho Guo Shun, Business, Investment Advisor
  • Arijit Bhattacharyya, Founder, and CEO, Virtualinfocom
  • Darwin Ling, Founder and General Partner at Good AI Capital
09:30 AM - 10:45 AMOpening Keynotes: Global Leadership in Data, AI and Healthcare Sector By VariousGlobal Data and AI Leadership
Moderator: Prasun J Mishra, Ph.D., Founder and CEO AAPM
  • Erika Brown, CEO/Co-Founder PALTOWN Development Foundation, Patient Advocate
  • Ritesh Jain, Co-Founder, Infynit, Former COO HSBC, Advisor G20 GPFI, HBR-Harvard Business Review and Massachusetts Institute of Technology-MIT
  • Tudor Oprea, M.D. Ph.D., Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine, University of New Mexico
  • Piyush Sharma, Former CEO Zee News, EIR, UCLA Anderson School of Management and Advisor, Stanford Seed

 

 

10:45 AM - 11:15 AMAAPM initiatives
Prasun J Mishra, Ph.D., Founder and CEO AAPM
11:15 AM - 12:00 PMLightning Talks: DANS2021 By VariousTech and Precision Medicine

Moderator: Suraj Saksena, Ph.D., Science, and Technology Leader, BD

  • Tatyana Kanzaveli, MS, Founder, and CEO of Open Health Network
  • Mohan Uttarwar, Founder and CEO, INDEX.AI
  • Asad Zaidi, MBA, CEO, Epinex Diagnostics and RedApple Digital Health
  • Mat Chacon, MBA, CEO Doghead Simulations
  • Pratip Chattopadhyay, Ph.D., Associate Professor and founding Director of NYU Langone Health’s Precision Immunology Laboratory
12:00 AM - 01:00 AMAI-Driven Translational Research and Diagnostics By VariousData and PM

Moderator: Kamala K Maddali DVM Ph.D., President, Health Collaborations and VP, Deep Lens

  • Kristine Mechem Ph.D., VP Diagnostics at Health Advances
  • Mark Rees, Ph.D., SVP R&D and Innovations StatLab
  • Bassam El-Fahmawi, M.Sc., Ph.D. President CTO, Mawi DNA Technologies
  • Pravin Mishra, MBA, Ph.D., Director, Ohio State University Cancer Center
  • Steven A. Bogen, MD, Ph.D., CEO, Boston Cell Standards, Medical Director, Clinical Chemistry Laboratory, Tufts Medical Center
01:00 PM - 01:45 PMClosing Keynotes: Big Data Challenges to Facilitate the Implementation of Precision Medicine By VariousData and PM

Moderator: Prasun J Mishra, Ph.D., Founder and CEO AAPM

  • Lynsey Chediak, Lead, Global Health at World Economic Forum
  • Tudor Oprea, M.D. Ph.D., Professor of Medicine and Chief, Translational Informatics Division, Department of Internal Medicine, University of New Mexico
  • Piyush Mathur, MD., Founder, BrainX, Anesthesiologist/ Intensivist, Cleveland Clinic
  • Marcin von Grotthuss, Ph.D., Principal Scientist, Takeda
  • Hunter Whitney, Sr. Director, UX at RiskIQ, Author of Data Insights, and Instructor, UC Berkeley Ext.
01:45 PM - 02:00 PMClosing Remarks: Conclusion of Day 1

Prasun J Mishra, Ph.D., Founder and CEO AAPM

Gold Ticket

$80/ person
  • Get Acess to all Sessions
  • Unlimited Coffee and Foods
  • Meet with Favourite Speakers
  • Access to all Audio and Video Files
  • Get Acess to all Sessions
DINESH KOTAK, MD
DINESH KOTAK, MDDINESH KOTAK, MD Chair- Departmental Technology Leads – Oncology, Kaiser Permanente

"Thanks Prasun, for invite and the award. It was a privilege to share the stage with such an accomplished and committed panel and an engaged and well-informed audience."

NISHIT DOSHI, PhD
NISHIT DOSHI, PhDDirector, Roche Molecular Systems

"Really enjoyed moderating the panel discussion on "New technologies and breakthroughs in cancer care" at the American Association of Precision Medicine. Excellent event, very well organized! Looking forward to the annual meeting."

PANKAJ BHARGAVA, MD
PANKAJ BHARGAVA, MDVP, Oncology TA Head Gilead Sciences, Former Professor Harvard Medical School

"Thanks all, honored to accept this award on behalf of our terrific teams at Gilead and Kite! Great forum!! Thanks Prasun and the AAPM team!"

GARY STARLING, PhD
GARY STARLING, PhDAssociate Vice President at Merck

“Pleased to have been able to accept this award on behalf of Merck's amazing Keytruda Clinical teams at the DANS meeting last week. [ ….] Congratulations to the Merck Oncology Clinical Development team.”

Get Your Tickets Today, Before they are Sold Out!

FAQ’s

Commonly asked questions about the event.

Contact Us

Explore our pst events and enjoy!

Send Message

If you have any questions or just want to get in touch, use the form below. We look forward to hearing from you!

    AAPM 2020 is Hosted Virtually